Platinum coordination to RNA by Chapman, Erich G., 1984-
 
 
 
 
PLATINUM COORDINATION TO RNA 
  
by 
ERICH G. CHAPMAN 
A DISSERTATION 
Presented to the Department of Chemistry 
and the Graduate School of the University of Oregon 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy  
December 2010 
ii 
 
 
 
 
“Platinum Coordination to RNA,” a dissertation prepared by Erich G. Chapman in partial 
fulfillment of the requirements for the Doctor of Philosophy degree in the Department of 
Chemistry. This dissertation has been approved and accepted by:  
 
 
 
 
____________________________________________________________ 
Michael M. Haley, Chair of the Examining Committee 
 
 
 
________________________________________ 
Date 
 
 
 
Committee in Charge: Michael M. Haley, Chair 
    Victoria J. DeRose, Advisor 
    David R. Tyler 
    Andrew J. Berglund  
    Eric A. Johnson  
 
 
Accepted by: 
 
 
 
 
____________________________________________________________ 
Dean of the Graduate School 
iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2010 Erich G. Chapman  
iv 
 
 
 
 
An Abstract of the Dissertation of 
 
Erich G. Chapman for the degree of Doctor of Philosophy 
   
in the Department of Chemistry to be taken December 2010 
 
Title: PLATINUM COORDINATION TO RNA  
 
 
 
Approved:  _______________________________________________ 
Victoria J. DeRose 
 
 
 
 
Since discovery of its biological effects in the late 1960’s, cisplatin (cis-
diamminedichloroplatinum(II)) has become one of the most broadly-prescribed cancer drugs in 
use today. A majority of efforts to understand the metallobiochemistry of this drug have focused 
on describing the interactions of cisplatin-derived Pt(II) complexes with DNA. Drug binding to 
this “high value” cellular target is believed to trigger the apoptotic pathways that underlie 
cisplatin’s cytotoxic effects. Although RNA is chemically similar to DNA and responsible for 
accurately transferring, regulating, and transforming the same genetic information that is stored 
within the DNA genome, surprisingly little is known about platinum(II) drug binding to RNA. 
Accordingly, the first three chapters of this dissertation describe efforts to address questions 
regarding cisplatin coordination to RNA on the molecular scale. Chapter I reviews fundamental 
aspects of how metal complexes interact with nucleic acids, highlighting the bioinorganic 
chemistry of platinum(II) antitumor drugs. This chapter also introduces the idea that drug binding 
to RNA may form an important part of how these complexes work in the cell. Chapter II 
describes cisplatin crosslinking between RNA nucleobases located on opposite sides of the 
internal loop of an RNA subdomain derived from the catalytic core of the spliceosome. Chapter 
v 
 
 
III describes how platinum adducts disrupt the activity of RNA processing enzymes similar to 
those that are necessary for maturation, maintenance and recycling of the transcriptome. Chapter 
III also describes the reversal of RNA platination using thiourea.   
The chemistry of platinum(II) is also characterized by preferential coordination to sulfur 
ligands, or thiophilicity.  Incorporating this property into RNA chemistry, Chapters IV and V 
describe the reaction of platinum(II) complexes with phosphorothioate-substituted RNAs. 
Chapter IV describes engineering platinum(II) crosslinks in the Hammerhead ribozyme through 
the targeting of a platinum(II) complex to a specific phosphorothioate substitution installed in the 
active site of this catalytic RNA. Chapter V outlines efforts to characterize the cleavage and 
isomerization reactions promoted by platinum(II) coordination to phosphorothioate-substituted 
RNAs. Finally, Chapter VI summarizes the insights gained throughout the course of our studies 
and provides an outlook on the future of platinum-RNA chemistry.  
This dissertation includes co-authored material and previously published results. 
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CHAPTER I 
 
PLATINUM COORDINATION TO RNA 
 
 
Introduction and Recognition of the Contributions of Others in This Dissertation: 
     This dissertation describes platinum(II) coordination to ribonucleic acid (RNA) and includes 
contributions from a number of individuals who have helped me explore this interesting type of 
chemistry. Dr. Victoria DeRose initiated this line of research while at Texas A&M University and 
has overseen its development since, shaping many aspects of the studies described in subsequent 
chapters. In addition to her ongoing scientific guidance, Dr. DeRose has provided extensive 
assistance in editing the following chapters for their inclusion in this dissertation. Alethia 
Hostetter has worked along side me for the past five years and has shared many important ideas 
that have influenced how our research group thinks about the biological effects of Pt(II) antitumor 
drugs. Studies she performed, characterizing the rate of Pt(II) coordination to various RNA and 
DNA constructs, are included in Chapter II. Maire Osborn, a recent addition to the DeRose group, 
has similarly provided us with new ideas and interesting hypotheses about how Pt(II) complexes 
may influence cellular function. Several of her ideas are introduced in Chapter I as part of 
building the case that Pt(II) coordination to RNA may be important component of the biological 
activity of Pt(II) antitumor drugs. Chapter IV describes Pt(II) crosslinking in the core of the 
Hammerhead ribozyme. Here, Luke Ward taught me about the structure of an all-RNA active site 
and about how RNAs folds. Chapter V, which describes a series of phosphoryl transfer reactions 
initiated by Pt(II) coordination to a phosphorothioate substitution, includes data from a trio of 
exceptional rotation students. Emma Downs, Josiah Vincek and Alex Kendall all contributed 
ideas and experimental data that have helped us form the mechanistic hypothesis presented within 
this chapter. I am grateful to these individuals and to many others who have shared in the 
scientific pursuits described in this dissertation and hope that I will be able to reciprocate in kind.  
     Parts of this chapter have been adapted from: “Binding of Kinetically Inert Metal Ions to 
RNA: The Case of Pt(II)” Chapman, E.G.; Hostetter, A; Osborn, M.; Miller, A.; DeRose, V.J.  
In Metal Ions In Life Sciences: Structural and Catalytic Roles of Metal Ions in RNA; Sigel, A.; 
Sigel, H.: Sigel, R.K.O. Eds. Royal Society of Chemistry, Cambridge, UK, 2011 in press. 
 
 
  2 
The Antitumor Drug Cisplatin: 
     “I’ve just cured cancer!” are reportedly the words Dr. Barnett Rosenberg first exclaimed after 
discovering that E. coli. cells grown in the presence of an electric current did not divide as 
normal, but instead elongated to 50-60 times their normal length.1,2 Immediately realizing the 
enormous therapeutic potential for whatever was causing this behaviour, researchers at Michigan 
State University conducted a series of careful control studies demonstrating that a soluble Pt salt 
produced by hydrolysis reactions occurring at the electrodes used in these experiments was 
responsible for these astonishing effects.2 Follow-up studies revealed that the square-planar Pt(II) 
complex cis-Pt(NH3)2Cl2, (cisplatin, cis-diamminedichloroplatinum(II), 1) potently inhibited E. 
coli cell division.3 The discovery of the biological activity of this molecule marked a new era in 
bioinorganic chemistry.4 The ensuing development and successful clinical application of Pt(II) 
antitumor drugs has transformed the treatment of many cancers5 and inspired vigorous research6,7 
into the molecular basis of how relatively simple Pt(II) complexes are able to treat a disease as 
notoriously complex as cancer.8 Over 40 years of research have now been invested in developing 
a model in which neutral Pt(II) drug complexes accumulate9 in a cell, subsequently becoming  
‘activated’ by the loss of anionic ligands. The cationic Pt(II) species that result can coordinate to 
a variety biomolecular targets.10 Currently, the activity of Pt(II) antitumor drugs is ascribed to 
their ability to form kinetically-inert adducts with adjacent purine nucleotides within regions of 
genomic DNA, distorting the double helical structure of the genetic code.10-12 Sensing of these 
types of Pt(II) lesions by proteins responsible for ensuring the fidelity of the information stored 
within the genome13 can go on to trigger programmed cell death, or apoptosis.14,15 Because drug 
binding to DNA is considered to be the determining factor in initiating apoptosis many of the 
basic principles that govern Pt(II) coordination to DNA have been elucidated.16 Despite RNA’s 
chemical similarity to DNA and its critical roles in accurately transferring, regulating and 
transforming the very same genetic information that is contained within the DNA genome, 
relatively little is known about how cisplatin coordinates to RNA. This chapter reviews the 
fundamental chemical principles of how Pt(II) antitumor drugs coordinate to nucleic acids, using 
cisplatin as the primary example to illustrate how Pt(II) complexes coordinate in complex RNA 
architectures. This chapter also introduces the idea that this type of coordination, when occurring 
in the cell, may disrupt important cellular processes dependent on RNA fidelity. Combined, these 
topics form the basis for the studies presented in subsequent chapters. 
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!
1 2 3  
Figure 1.1. Structures of Pt(II) antitumor drugs: 1) Cisplatin 2) Carboplatin 3) Oxaliplatin.  
 
Platinum(II) Coordination Chemistry: 
     Compared to the scaffolds of many chemotherapeutics the structure of cisplatin, an 11-atom 
square-planar Pt(II) metal complex, is remarkably simple. Kinetically-labile chloride ligands are 
arranged opposite to relatively exchange-inert ammine ligands in a cis- geometry around a d8 
Pt(II) center. This basic geometry is characteristic of the Pt(II) antitumor drug family (Figure 1).  
The bioactivity of these compounds is based on a series of ligand exchange reactions occurring 
around Pt(II). Because these types of reactions are central to the biological activity of Pt(II) 
complexes it is useful to review basic principles of Pt(II) coordination chemistry prior to 
proceeding to a discussion of the reactivity of Pt(II) antitumor drugs in the cell. 
     The coordination chemistry of Pt(II) is highlighted by the propensity of the metal to form 
kinetically-inert complexes with “soft” σ-donating ligands. This class of ligands is represented by 
cyanato, thiocyanato, sulfido, thiolate, thiol, and phosphine ligands as well by more intermediate 
σ-donors such as ammines and imines.17 Other types of ligands are observed to form more 
kinetically-labile complexes with Pt(II) that undergo ligand substitution reactions through an 
associative mechanism, common to 16e- transition metal complexes. The preference of Pt(II) to 
form stable complexes with strong σ-donating ligands has made the metal a classical platform for 
experiments demonstrating the “trans effect”.17,18 This effect describes the observation that 
certain classes of ligands strongly labilize ligands located on the opposite side of a metal center. 
This “effect” is actually the combination of both kinetic and thermodynamic influences on ligand 
substitution reactions. Strong σ-donating ligands, observed to demonstrate large trans effects, 
weaken the strength of the metal-ligand bond opposite to their position and decrease the ground 
state stabilization associated with ligand coordination to this site. Conversely, strong π-accepting 
ligands demonstrate large trans effects based on their ability to accept electron density from metal 
based dxz molecular orbitals during the trigonal bipyramidal transition state that is passed through 
during ligand substitution. This stabilization decreases kinetic barrier involved in ligand 
substitution and in turn increases the rates of these types of reactions.17,18 Combined with Pt(II)’s 
preference for soft ligands, the trans effect is characteristic of coordination chemistry of square- 
  4 
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Figure 1.2. Uptake and biomolecular targets of Pt(II) antitumor drugs. 
 
planar Pt(II) complexes and has a large effect on how these complexes work in biological 
settings. 
 
Cisplatin Chemistry in the Cell: 
     Typically, cisplatin and other Pt(II) antitumor drugs are administered intravenously into the 
bloodstream where a high chloride concentration (~100 mM) is believed to prevent loss of the  
molecule’s chloride ligands until it enters a cell either by active uptake through copper transport 
proteins19 or by passive diffusion (Figure 1.2).9 Once inside the cell, a lower chloride 
concentration (~2mM) facilitates the exchange of cisplatin’s chloride ligands, giving rise to the 
equilibria depicted in Scheme 1.1.20 Many factors, including the identity and orientation of the 
Pt(II) ligand set, pH and the surrounding ionic environment, influence the rates and mechanisms 
these reactions.21    
     Once positively charged, cationic Pt(II) complexes undergo further ligand substitution 
reactions to coordinate and form kinetically inert adducts with ‘soft’ biomolecular nucleophiles 
(Figure 1.2). Appropriate Pt(II) coordination sites are found in a variety of small molecules, 
protein residues and on RNA and DNA nucleobases.10 In proteins and small molecules thiol, 
thioether, and imidazolic functionalities (on cysteine, methionine, and histidine residues 
respectively) seem to be particularly targeted. Pt(II) coordination to the small, cysteine-containing 
tripeptide glutathione has long been implicated in attenuating the effects of Pt(II) anticancer 
compounds.22 A recent crystal structure depicting Pt(II) coordination to cysteine residues in a 
human copper chaperone protein23 similarly highlights the propensity of Pt(II) compounds for 
coordinating to these types of ligands.  The reaction of Pt(II) species with DNA and RNA is 
subsequently considered, however the significant body of research that has been  
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Scheme 1.1. Cisplatin equilibria in water. Kinetic and pKa values at 25 °C taken from reference 
20. 
 
devoted to discovering new bioactive Pt(II) complexes24 bears mention here as the majority of 
these efforts have focused on tuning the reactivity of Pt(II) complexes to increase their cellular 
and molecular level selectivity. 
 
Cisplatin Analogues: 
      Despite the synthesis and screening of thousands of Pt(II) centered molecules,25 in addition to 
cisplatin, only two of these have been approved by the U.S. Food and Drug administration26 for  
use in chemotherapy: carboplatin (cis-diammine (cyclobutanedicarboxylato) platinum(II), (2)), 
and oxaliplatin (cis-oxalato-(trans-1)-1,2-(diaminocyclohexane)platinum(II),(3)) (Figure 1.1). 
The variation of Pt(II) ligands in the compounds represents two parameters that have been found 
to be important in determining efficacy of Pt(II) antitumor complexes. The dicarboxylate ligand 
of carboplatin is believed to slow hydration of the Pt(II) center27 and tune the pharmokinetics of 
the drug in vivo. It is interesting to note that despite different in vivo activity, coordination of 
carboplatin to biomolecular targets results in the same types of Pt(NH3)2-biomolecule adducts as 
the parent compound cisplatin.  In contrast, the chiral ammine ligand of oxaliplatin is kinetically 
inert and expected to remain bound to Pt(II) following coordination to a targeted biomolecule. 
The activity of this drug in cisplatin-resistant cell lines28 is believed to result from the formation 
of DNA lesions that are differentially recognized than those formed by cisplatin.29 Combined, the 
efficacy of carboplatin and oxaliplatin demonstrate that simple changes in the Pt(II) ligand set can 
give rise different activity profiles for Pt(II) antitumor drugs. Synthetic attempts to tune the 
reactivity of Pt(II) chemotherapeutics through simple changes in the primary ligand sphere have 
now given way to the pursuit of more advanced strategies, primarily focused on drug delivery. 
The conjugation of Pt(IV) prodrugs to nanoscale sized “longboats”30 and “warheads”31 for 
selective delivery into cancer cells exemplify modern efforts.   
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Figure 1.3 Structures of RNA and DNA nucleotides. Nucleobase numbering conventions are 
indicated in blue. Ribose numbering conventions are indicated in green. Approximate pKa values 
of positions on the nucleobases are indicated in red. Chemical differences between RNA and 
DNA are highlighted in gray. 
 
Platinum(II) Coordination to Nucleic Acids: 
     Pt(II) coordination to DNA to has been linked to the induction of apoptosis,32 making an 
understanding of this process critical to the development of a comprehensive description of the 
biological activity of Pt(II) antitumor drugs. Accordingly, extensive research efforts have been 
directed toward describing the metallobiochemistry of Pt(II) and DNA.33 Significantly less 
research has been performed describing the reactions of Pt(II) species with RNA, however the 
chemical similarity between the two biopolymers allows many aspects of the chemistry involved  
to be considered simultaneously.  Here, it is useful to consider the interaction of Pt(II) complexes 
with DNA and RNA hierarchally, proceeding from the basic chemical structure of these 
biopolymers up to secondary and tertiary structural parameters that effect Pt(II) coordination to 
nucleic acids.  
 
The Influence of Primary Structure on Platinum(II) Coordination to RNA and DNA: 
     Both DNA and RNA are polyanionic biopolymers formed by nucleotide monomers.32 The 
chemical structure of these nucleic acids consists of three main components: i) a phosphodiester 
backbone forming linkages between 3’ and 5’ positions on ii) a β-D-ribose- or 2’-deoxy-ribose 
rings substituted at the 1’ position with a iii) purine or pyrimidine nitrogenous base.34,35 Together 
these components define the primary structure of a nucleic acid. The numbering conventions used 
in describing the structure of these biopolymers along with the pKa values of various 
functionalities are indicated in Figure 1.3.36 The primary chemical difference between RNA and 
DNA is the presence of the hydroxyl group at the 2’ position of the RNA ribose ring. While not 
directly involved in coordinating Pt(II), this functionality is critical to many of the biological 
roles of RNA. 
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Figure 1.4. Major Pt(II)-DNA adducts. The relative abundance of these adducts occurring in 
DNA isolated from cisplatin treated cells is indicated below each adduct. 
 
     Because Pt(II) preferentially coordinates to ‘soft’ nucleophiles, only a limited subset of the 
positions on RNA and DNA are typically considered to be targets for Pt(II) binding.  These 
include the N7 positions of both adenine and guanine as well as the N3 position of cytosine and 
N1 position of adenine.37 Typically, Pt(II) complexes with two open coordination sites are 
observed to form macrochelate complexes between the N7 atoms of adjacent purine nucleotides.38 
Kinetic preference for initial, monofunctional Pt(II) coordination to the N7 of guanosine over the 
N7 of adenosine has recently been proposed based on the ability of a Pt(II) NH3 ligand to form 
hydrogen bonds with the O6 keto oxygen of guanosine.39 Differences in the electronics of the N7 
atom of each purine base have also been proposed to help rationalize the observation that G 
nucleotides are included in each of Pt(II) adducts observed in DNA isolated from Pt(II)-treated 
cells (Figure 1.4).33  As described below, the secondary and tertiary structure of DNA and RNA 
also play an important part in determining where Pt(II) will coordinate to these molecules.  
 
The Influence of Secondary Structure on Platinum(II) Coordination to RNA and DNA: 
     Folding of RNA and DNA biopolymers is driven by a combination of hydrophobic effects and 
the stabilization associated with the formation of hydrogen bonds between complementary purine 
and pyrimide nucleobases. In DNA, folding most typically results in the formation of a double 
helical structure. In RNA similar helical structures are formed but are accompanied by a myriad 
of other motifs (Figure 1.5).40 While principles that govern Pt(II) coordination to the diverse 
range of secondary structures adopted by RNA have not been developed, many aspects of how 
cisplatin coordinates to DNA double helices have been described (Figure 1.6).10 
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Figure 1.5. Schematic representation of RNA secondary structures. 
 
 
Table 1.1. Structural parameters of helical nucleic acids. Values from reference 35.  
 
     Differences between the major helical conformations of RNA and DNA may influence how 
Pt(II) coordinates to each biopolymer. As shown in Table 1.1 the structural parameters of the A-
form helix adopted by RNA are significantly different that those of the B-form structure adopted 
by DNA.35 In DNA, Pt(II) coordination typically takes place to the N7 atoms of neighboring 
purine nucleotides. These positions are located in the wide, relatively shallow major groove of the 
B-form double helix. In RNA, the equivalent positions are significantly more buried in the narrow 
and deep major grove of the A form helices (see Table 1.1). As described in the following 
sections this structural feature may preclude the formation of the same types Pt(II) adducts 
observed in DNA. 
 
The Influence of Tertiary Structure on Platinum(II) Coordination to RNA and DNA: 
     In cells, DNA that is not actively being transcribed or replicated is typically coiled around 
nucleosomes and packaged in chromatin. Few studies have addressed the platination of DNA in 
this structural context.  Recent findings, that site-specific Pt(II) adducts installed prior to DNA 
winding around nucleosomes disrupt nucleosome positioning,41,42 represent the first inroads made 
toward understanding platination in these situations. Accordingly, the influence of tertiary 
structure in determining Pt(II) adducts formed with DNA remains to be explored. 
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Figure 1.6. Structure of the major cisplatin adduct formed with DNA and factors affecting Pt(II) 
coordination to DNA. Structure generated using coordinates in reference 47. 
 
In contrast to DNA, RNA folding results in the formation of incredibly complex molecular 
architectures which include specific and pre-oreganized metal binding sites34,43,44 as well as 
solvent-excluded folds where nucleobase pKa’s can be significantly different from those observed 
in free solution.45,46 Consequently, these structures greatly expand the chemical space in which 
Pt(II) complexes may find appropriate coordination geometries to form drug-biomolecule 
adducts. The following section describes the studies that have characterized Pt(II) coordination to 
RNA to date.  
 
Examples of Platinum(II) Coordination to RNA: 
     A number of recent studies have described the formation of Pt(II) adducts formed with 
isolated RNAs (Figure 1.7). These investigations have examined cases ranging from the 
platination of relatively short, single-stranded RNAs48 to studies involving cisplatin coordination 
to intact bacterial ribosomes.49 In accordance with the observations above, an emerging feature of 
this research seems to be ability of Pt(II) complexes to coordinate in non-Watson-Crick base-
paired regions of RNA.  
     Several preliminary studies, conducted shortly after the discovery of cisplatin’s antitumor 
properties, sought to identify Pt(II) binding sites within tRNAPhe by soaking the compound into 
pre-formed RNA crystals or by reacting Pt(II) complexes with the RNA in high ionic strength 
conditions similar to those used in crystallization.50-52 In the earliest of these studies, Clark and 
coworkers reacted both cis- and transplatin with tRNAPhe at 4°C for 3 days in solutions containing 
high concentrations of Mg2+, spermine and 1,6-n-hexane-diol.50 Using thin-layer chromatography 
to characterize RNA fragments produced by nuclease digestion of platinated tRNAPhe, the authors  
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Figure 1.7. Examples of platinated RNAs. RNA structures that have been studied include the 
model 5’-U5XXU5-3’ (X1/2 =A or G),48 a purine-rich internal loop derived from the spliceosome 
(BBD),53 an RNA hairpin (RNAI),54 tRNA,50,52-54 hairpin models for the tRNA acceptor stem 
(sMhAla)54,55 and anticodon loop (acMhAla),55 intrastrand-to-interstrand cross-linking in RNA 
duplexes,56-58 a site on the ribosomal small subunit,49 and a small purine-rich strand.59 Pt(II) 
adduct identification has relied on mapping techniques with the exception of low-resolution 
crystallography of tRNA mentioned in the text. While tRNAAla is shown, several of the 
crystallographic studies mentioned in the text were performed using tRNAPhe. The binding sites 
identified in these studies are indicated using triangles and are overlayed on the tRNAAla 
sequences. 
 
identified a major transplatin binding site within the purine-rich anticodon loop of the RNA and a 
second, minor Pt(II) binding site within loop III. Surprisingly, under the conditions used in this 
study, cisplatin was not observed to coordinate to the RNA. A second investigation carried out by 
soaking Pt(II) complexes into pre-formed tRNAPhe crystals produced somewhat different results.51 
While only relatively low-resolution tRNAPhe structures were obtained (5.5Å), the authors 
identified both transplatin adducts described previously and additional Pt(II) binding sites at G18 
in the dihydrouridine loop and at A73 located in the molecule’s acceptor stem. Contrasting the 
earlier report however, this study also identified cisplatin adducts formed at both G15 and G18 in 
the D arm of the tRNA. In an independent, but very similar study, Dewan later reported a 6Å 
Pt(II)-soaked tRNAPhe structure with four cisplatin binding sites.52 The low resolution of these 
crystals, reportedly unavoidable due to the structural distortions caused by Pt(II) binding, 
prevented a detailed analysis, however electron density indicative of Pt(II) binding is apparent at 
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G3-G4, C25-mG26, G42-G43-A44-G45 and at A64-G65. The combined results of these three 
studies are overlaid on the secondary structure of tRNAAla in Figure 1.7. 
     More recent biochemical studies conducted by Elmroth and co-workers have employed full 
length tRNAAla as well as hairpin models of the molecule’s anticodon loop and acceptor stem to 
provide several interesting insights regarding the sequence and structural specificity of Pt(II) 
binding to these RNAs.54,55 By monitoring shifts in the dPAGE mobility of platinated RNAs, it 
was found that in the hairpin model of the tRNAAla acceptor stem (sMhAla, Figure 1.7), 
replacement of a native G•U wobble pair with a fully-complementary G-C base pair inhibits 
platinum binding to this RNA. Additionally, attachment of a 5’-terminal phosphate within the 
same region of the RNA alters the distributions of products observed upon platination. In the 
hairpin model of the tRNAAla anticodon stem, substitution of a natural UG sequence in the 
terminal loop for a GG sequence increases the rate of platination observed for this RNA and 
suggests that, similar to what is observed in DNA, Pt(II) complexes target neighboring purine 
sequences in RNA. Combined, these results highlight the influence of sequence and local 
structure in determining in vitro Pt(II) interactions with RNA.  
     Because non-Watson-Crick base-paired regions of RNA form the core of many functional 
RNAs, understanding how Pt(II) complexes coordinate to these structures is important in 
determining how Pt(II) antitumor drugs may affect RNA processes. The spliceosome is an 
incredibly complex RNA-protein machine responsible for removing intronic sequences from pre-
mRNAs. The catalytic core of the spliceosome is proposed to be comprised of the U2-U6 snRNA 
complex.60 In efforts to understand how cisplatin coordinates to structured regions of RNA, our 
lab has recently characterized how the drug binds to a 41nt RNA subdomain of the U2-U6 
complex, termed ‘BBD’ for ‘branch-bulge domain’ (Chapter II).53 BBD RNA consists of a 
hairpin structure in which base-paired regions flank a purine-rich, asymmetric internal loop 
(Figure 1.7). Reaction of this RNA with an aquated form of cisplatin results in the formation of a 
novel, Pt(II)-induced intramolecular crosslink. While the structure of this RNA is currently 
unknown, the nucleotides involved in forming this crosslink have been proposed as metal ion 
binding sites in the full U2-U6 snRNA complex.61,62 In light of this information, it is thought-
provoking to speculate that cisplatin may compete with native metal ion binding sites in RNA. 
This type of mimicry would be particularly interesting as metal ions often mediate important 
tertiary contacts between interacting RNA domains63 where crosslinking could potentially disrupt 
the dynamic function of these structures. 
     In another recent example of cisplatin coordination to a complex RNA structure, Rijal and 
Chow have reported how Pt(II) complexes may be used as a chemical probes for identifying 
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solvent-exposed purine nucleotides in intact bacterial ribosomes.49 Stable platinum adducts 
resulting from both in vivo and in vitro platination were identified in helix 24 of E. coli ribosomes 
using primer extension to detect Pt(II)-dependent halts in reverse transcription. Using this 
method, it was found that several G nucleotides located in non-Watson-Crick base-paired regions 
of the RNA were targeted by cisplatin. Pt(II) coordination to these nucleotides provides another 
example of platination occurring within regions of complex RNA structure, notably even in the 
presence of competing GG sequences in nearby helical regions of the same RNA.  
 
RNA Crosslinking by Transplatin and Platinum(II)-Drug Conjugates 
     The nucleic acid coordination properties of Pt(II) complexes have inspired research seeking to 
use these types of compounds as sequence-specific RNA crosslinking reagents and as scaffolds 
upon which to construct new RNA-targeting drug conjugates. 
     In studies aimed at determining how transplatin adducts distort nucleic acid structure it was 
discovered that pre-formed 1,3 G*pNpG* transplatin adducts (where “*” denotes a platinated 
nucleotide) in DNA readily rearrange into intermolecular crosslinks when annealed to 
complementary oligonucleotides.56-58 Subsequent mechanistic studies have shown that 
isomerization reactions between 1,3 G*pNpG* transplatin adducts and complementary 
oligonucleotides are sequence-specific,64 can result in unusual G-N7* to C-N3* crosslinks,57 and 
are also observed using 2’-OMe65 and other chemically modified RNAs. Further work has shown 
that transplatin- modified 2’-OMe RNAs66 and cisplatin-modified RNAs67,68 can be used as anti-
sense oligos for attenuating gene expression in cell lysates and in living cells.  
     Work in advancing RNA as a drug target69 has prompted synthesis of a pair of Pt(II)-drug 
conjugates.  Tethering neomycin B and guanidinoneomycin B to a square planar Pt(II) complex, 
Tor and coworkers70 have shown that Pt(II)-drug conjugates can demonstrate substantial 
selectivity in targeting RNA over DNA as well as can form intramolecular crosslinks in RNA. 
Similarly, a Pt(II)-estradiol conjugate has also recently been shown to coordinate to tRNA.71 
 
Platinum(II) Coordination to RNA on the Molecular Scale: 
     The preceding sections describe how Pt(II) complexes coordinate to RNA on the molecular 
scale. Cumulatively, the largest differences displayed in how Pt(II) species coordinate to RNA 
versus DNA seems to be that platination is favored in non-helical regions of RNA, perhaps due to 
the steric inaccessibility of purine N7 targets within A-form helices. As Pt(II) coordination to 
increasingly complex structures is explored it seems likely that drug binding to non-Watson-Crick 
base-paired regions of RNA structure will emerge as a theme in these studies. Because such 
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regions are critical in forming RNA-RNA and RNA-protein contacts, drug binding within these 
regions could be envisioned to disrupt the function of important cellular machines. The following 
sections describe the limited number of reports that have examined this type of disruption. 
Combined, these studies portray the potential of Pt(II) treatment to interfere in almost every stage 
in the lifecycle of cellular RNAs.  
 
Platination of RNA in the Cell: 
     An important aspect in determining how Pt(II) targeting of RNA may factor into the biological 
activity of Pt(II) antitumor drugs is the extent to which RNA is platinated in vivo. Surprisingly, 
while many aspects of the biology of Pt(II) antitumor compounds have been extensively 
characterized, only a limited number of studies have quantified drug binding to RNA and DNA 
simultaneously. 
     In the earliest of these studies Pascoe and Roberts quantified Pt(II) binding in HeLa cells 
following treatment with 5-400 uM cisplatin.72 After fractionation of DNA, RNA and protein 
components by phenol chloroform extractions and selective precipitations, the authors quantified 
the amount of Pt(II) bound to each type of macromolecule using atomic absorption spectroscopy. 
Interestingly, the results of these experiments show that when considered on a Pt(II) per gram 
biomolecule basis, significantly more Pt(II) is bound to RNA than DNA.  These authors also 
pursued similar experiments with the less bioactive transplatin isomer and show that despite 
higher levels of cellular accumulation and more extensive binding to RNA, DNA and protein 
fractions, the trans complex is significantly less cytotoxic. 
     A more recent study, which similarly assessed levels of Pt(II) coordination to different types 
of biomolecules in HeLa cells, measured the extent of incorporation of metastable 195mPt(II) 
complexes into the DNA, RNA and protein components in drug-treated cells.73  In these 
experiments 195mPt(II) was found to accumulate to a large extent in protein fractions, and while 
RNA and DNA are both significantly less platinated, they are found bind Pt(II) in an 
approximately equal ratio. Interestingly, this ratio changes over time with drug binding to DNA 
leveling off by 4 hr following drug treatment while cellular RNAs continue to accumulate Pt(II). 
     Combined these studies raise important questions about which types of cellular RNAs are 
targeted by Pt(II) antitumor drugs and whether additional factors such as cellular localization or 
cellular lifecycle may effect these distributions. 
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! 
Figure 1.8. RNA processes inhibited by Pt(II) compounds as determined from studies in cells, 
cell extracts, and in vitro. References: a) 74, 76-78 b) 53 c) 81 d) 80 e) 54,55 f) 49 g) 79, 82-83 h) 
48. Figure created by Maire Osborn. 
 
Platinum(II) Antitumor Drugs Influence Transcription, Translation, and Splicing: 
      In addition to RNA’s role in ferrying genetic information, RNA and RNP machines catalyze 
many critical reactions within the cell. It is interesting to imagine how structural damage inflicted  
by Pt(II) drug binding might affect the function of these intricate machines. Indeed, several 
reports have shown that platination can interfere with critical points in the lifecycles of cellular 
RNAs. These studies are, by necessity, carried out in chemically complex systems where it is 
challenging to ascribe a loss in function to a specific instance of drug binding, however the 
effects that have been described motivate detailed examination in future studies. 
     The earliest point at which platination has been observed to interfere with the function of RNA 
is during its synthesis. Several high resolution studies have shown that a single and specific Pt(II) 
adduct synthetically installed on a plasmid template blocks RNA synthesis by RNA polymerases 
in vitro,74 in cellular extracts,75 and recently in living cells.76 The structural basis behind this 
disruption was recently reported showing that a platinated DNA template is unable to gain access 
into the active site of RNA polymerase II.77 On the cellular level, platination has been shown to 
interefere preferentially with rRNA synthesis in HeLa cells accompanied by a redistribution of 
transcriptional machinery.78,79 
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     Following its synthesis, the majority of RNA in a cell is processed in some way before being 
used. One critical component of RNA processing involves the removal of non-coding, intronic 
sequences from pre-mRNAs by the spliceosome.  Platination has been observed to interfere with 
this process in HeLa cell nuclear extracts by disrupting the assembly of spliceosomal 
intermediates.80 The impact of platinating RNA components of the splicing machineries is further 
suggested by similar results showing the disruption of self-splicing by the Tetrahymena Group I 
Intron which takes place in the absence of protein cofactors.81 Interestingly, this study suggests 
that RNA crosslinking is responsible for the loss of activity.  
     The ribosome relies upon the concerted function of mRNA, rRNA, and tRNA. Platination of 
any of these types of RNA could foreseeably act as a wrench thrown into the cogs this cellular 
factory. Accordingly, in cellulo studies using rabbit reticulocyte lysate have demonstrated that 
platination of either pre-mRNA or rRNA components interferes with translation.82,83 Subsequent 
studies have suggested that this disruption is a combination of cisplatin’s ability to disrupt both 
initiation and elongation.78,82,83 Recent studies in both yeast and E. coli. demonstrating the 
formation of specific Pt(II) adducts on the ribosomes of Pt(II) treated cells complement these 
findings.49 It still remains very challenging however to assess if single Pt(II) adducts affect the 
function of a 2.5 MDa machine. 
 
Platinum(II) Coordination to RNA Disrupts RNA Processing: 
     RNA is processed in a number of ways throughout its cellular lifetime. Exonucleases work 
both to mature mRNA’s as well as dispose of them once they are no longer needed by the cell. 
Endonucleases cut at specific points within an RNA and act in a number of critical regulatory 
pathways including RNA interference pathways, and have recently been discovered to cleave 
tRNA in response to cellular stress. As Chapter III describes, each of these types of RNA-
processing enzymes are disrupted by platination of a substrate RNA. 
 
Determining the Effects of Platinating Cellular RNAs- A Daunting Task: 
     A cell is a complicated place. Cisplatin’s selectivity is largely based on relatively simple 
coordination chemistry, making soft nucleophilic sites on proteins, DNA and RNA all viable 
targets for Pt(II) antitumor drugs. Determining how drug targeting of only one of these types of 
molecules effects cellular function is a challenging task. Adding to this complexity, both proteins 
and RNA are critical components of many pathways that are monitored by the cell to ensure its 
own health. Pt(II)-interference with one of these processes could influence secondary signaling 
pathways, magnifying the effects of platinating just a single target. A growing appreciation of the 
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complex roles played by RNA in post-transcriptional gene regulation motivates future studies 
aimed at determining how platination may influence these processes. These investigations may 
simultaneously provide useful insight into many fundamental questions such as how the cell 
handles general RNA damage or how RNA regulatory pathways are used to respond to cellular 
distress.   
 
Summary and Bridge to Chapter II: 
     Chapter I provides a summary of the coordination chemistry of Pt(II) antitumor drugs as well 
as a survey of the limited number of studies that have suggested that platination of RNA may 
disrupt important processes within the cell. In line with this, Chapter II describes how cisplatin 
coordinates to a 41-nucleotide RNA subdomain derived from the spliceosome. These studies 
show rapid targeting of RNA by cisplatin and the formation of intramolecular, Pt(II)-induced 
crosslinks spanning an RNA internal loop. 
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CHAPTER II 
 
RAPID CROSSLINKING OF AN RNA INTERNAL LOOP BY THE ANTICANCER 
DRUG CISPLATIN 
 
 
Introduction: 
       This chapter includes contributions from Alethia A. Hostetter and Prof. Dr. Victoria J. 
DeRose. Alethia Hostetter characterized RNA and DNA platination kinetics, isolated the RNA 
used in mass spectrometry experiments and co-wrote the corresponding manuscript.  I identified 
the locations of platinum crosslinks in BBD and the SBBD construct, performed mass 
spectrometry experiments and also co-wrote the resulting manuscript. Prof. Victoria DeRose 
conceived the original focus of this research, guided experimentation, as well as edited and 
shaped the resulting article. The RNA subdomain used in this work was originally characterized 
by Sarah Tate and Dr. Janell E. Schaak as part of studies aimed at understanding the role of metal 
ions in RNA splicing. This chapter includes work published in the Journal of the American 
Chemical Society (2009, 131, 9250-9257, © 2009 American Chemical Society).   
 
Cisplatin Coordination to RNA:  
Cisplatin (cis-diamminedichloroplatinum(II)) is the flagship compound for a series of 
platinum(II) anti-tumor agents employed in the treatment of a wide range of cancers.1-3 Cisplatin 
activity involves intracellular exchange of the labile chloride ligands and ultimate coordination to 
“soft” biomolecular donor sites. In vivo, cisplatin is known to bind to multiple targets including 
DNA, RNA, proteins, and small-molecule ligands. Drug binding to adjacent purines on genomic 
DNA has been linked to the induction of apoptosis, a foundation of antitumor activity. Despite 
their prevalent use, a comprehensive understanding of additional drug-related biological 
processes is still forming for the platinum antitumor compounds.  
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Early studies that are often cited in identifying DNA as a target for cisplatin reveal that, on a 
per nucleotide basis, drug binding to DNA and RNA is roughly equivalent.4,5 Additional studies 
have shown that platinum drug treatment is capable of interfering with transcription,6-8 and that  
critical RNA-dependent activities such as splicing9 and translation5,10,11 are inhibited when 
measured in cell extracts.  Combined, these studies suggest that the binding of cisplatin-derived 
species to RNA may contribute to the drug’s in vivo effects. A limited number of studies have 
revealed further details concerning the interactions of cisplatin with RNA.  Elmroth, Chow, and 
coworkers have previously communicated enhanced reactivity and more pronounced dependence 
of reaction rate on ionic conditions for the reaction of a 13nt RNA hairpin in comparison with a 
DNA analog.12 Elmroth and coworkers have additionally suggested binding locations for cisplatin 
near the G•U wobble pair in a tRNAAla acceptor stem,13,14 and have explored platinum-RNA 
adducts for directing RNA silencing.15  Cisplatin has been shown by Danenberg and coworkers to 
inhibit in vitro activity of a Group I intron ribozyme.16 Very recently, Rijal and Chow have 
reported cisplatin as a structural probe to identify accessible purine nucleobases in bacterial 
ribosomes.17 These studies suggest intriguingly selective cisplatin-RNA reactivity, and call for 
more detailed kinetic analyses and comprehensive characterization of the nature of the platinated 
products in complex RNAs.  
A common characteristic of naturally-occurring metal sites in RNA is the involvement of 
ligands that are distant in primary sequence but brought into proximity in the folded RNA 
structure.18-20 By crosslinking two such ligands, cisplatin-induced chelation, whether in naturally 
occurring metal sites or novel target sites, has the potential to inhibit activities that depend on the 
dynamic nature of RNA. The spliceosome is an example of an RNA machine that is dependent on 
dynamic rearrangements for function.21,22 One key step in spliceosomal function is the formation 
of a complex between the U2 and U6 snRNAs that is implicated in the first step of pre-mRNA 
splicing.23 This chapter provides an in vitro analysis of the reaction between aquated cisplatin and 
a 41 nt RNA construct termed BBD (branch-bulge-domain) that contains the purine-rich internal 
loop formed from U2 and U6 snRNA strands (Figure 2.1).24 It shows that platinum forms a novel 
intrastrand cross-link across the internal loop of BBD and an interstrand cross-link in an 
analogous  two-piece construct. Additionally, this chapter describes that, under biologically 
pertinent ionic conditions, platination of both BBD and a related 40 nt RNA hairpin is ~5-fold 
faster than for a DNA hairpin analogue. MALDI-MS data are presented that complement the 
conclusions from corresponding biochemical studies. Taken together, these results indicate facile 
cisplatin-induced adduct formation across an RNA internal loop and fast platination kinetics of 
RNA oligonucleotides. 
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Figure 2.1. Derivation of the BBD RNA Sequence. a) Proposed secondary structure of the human 
U2:U6 snRNA core complex indicating the branch oligonucleotide.18 Conserved nucleotides are 
outlined in maroon. b) Predicted secondary structure of the BBD RNA subdomain used in this 
study, with invariant nucleotides again highlighted by maroon outline. 
 
Evidence of Platinum(II)-Induced RNA Crosslinking:  
     RNA and DNA oligonucleotides used in this study are shown in Figure 2.2a.  The BBD RNA 
subdomain contains a purine-rich internal loop flanked by helical regions, whereas the RNA and  
DNA hairpin sequences (RNA HP and DNA HP) are fully base-paired. In previous studies, 
reaction of RNA or DNA with cisplatin has resulted in product species that are typically observed 
to migrate more slowly when analyzed by denaturing polyacrylamide gel electrophoresis 
(dPAGE).25,26 Slower migration of platinated oligonucleotides is likely due to added molecular 
weight and a decrease in the overall charge of the nucleic acid through binding of a [Pt(NH3)2]2+ 
fragment. By contrast, cisplatin reaction with BBD results in a product species with higher 
mobility (Figure 2.2b).  Faster mobility under denaturing conditions may be caused by 
intrastrand crosslinking,27,28 which was hypothesized to occur across the purine-rich internal loop 
region of the BBD RNA. In order to test this hypothesis, the BBD internal loop sequence was 
embedded between two new duplex sequences, creating a two-piece “split” BBD construct 
(SBBDs, Figure 2.2a).  Platination of SBBD results in crosslinking of the two strands, as 
observed unambiguously by dPAGE (Figure 2.2c). Platination of the individual upper or lower 
SBBD strands does not result in a crosslinked species, although the presence of secondary 
platination sites is indicated by the dispersion of the dPAGE product bands (Figure 2.2c). These 
data indicate that cisplatin creates a crosslink across the internal loop of BBD RNA. 
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Figure 2.2. Crosslinking across the BBD internal loop. (a) Oligonucleotide sequences and 
predicted secondary structures. The BBD internal loop is highlighted in red. Differences in 
sequence relative to BBD are shown in blue. (b) Formation of a higher-mobility BBD product 
upon platination of BBD. (c) Confirmation of cisplatin-induced crosslinking in BBD internal loop 
sequence, showing products of platinum treatment with (i) BBD, (ii) SBBD, (iii) single strands of 
SBBD. Conditions: (b) 0.2 µM 5’32P-labeled BBD treated with indicated concentrations of 
cisplatin for 1.5hr in deionized water, analyzed by 18% denaturing PAGE, and visualized by 
autoradiograph; (c) 20 µM (0.2 nmol) RNA reacted with 10x cisplatin in 5 mM TEA (pH 7.8), 
12-15 hrs,  37 °C, analyzed by 20% denaturing PAGE, and visualized by staining with methylene 
blue. 
 
Identification of Crosslinked Nucleobases:  
In order to identify the specific bases involved in formation of an intrastrand crosslink, the 
proposed crosslinked product (BBD-XL) was isolated following dPAGE and mapped by partial 
alkali hydrolysis. Using 5’ end-labeled RNA, normal hydrolysis products are expected to be 
observable up to the 5’ side of the crosslinked site.28-30 Hydrolysis products that contain the 
crosslinked site will result in significantly higher molecular weight species with unusual gel 
mobilities, leaving a gap in the hydrolysis ladder following the 5’ crosslinked site.28-30 As 
displayed in Figure 2.3, clear BBD-XL hydrolysis products are observed for nucleotides 3’ to A8, 
but not at G9, identifying G9 as the major 5’ site involved in the internal crosslink. An additional 
faint band at U10 suggests G11 as a minor secondary site for platinum-induced crosslinking.  In the  
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a) b) 
 
Figure 2.3. Location of platinum crosslinks formed in BBD RNA. (a) The secondary structure of 
BBD representing the location of the cisplatin-induced crosslink found in BBD-XL. (b) Cleavage 
products produced by the alkali hydrolysis of isolated BBD-XL. Lanes from left to right. Control 
lanes (untreated BBD) C: Control 5’-end-labeled untreated BBD. T1: G-specific sequence ladder 
generated by partial nuclease digestion by RNase T1. U2: A-specific sequence ladder generated 
by partial nuclease digestion by U2 RNAse. OH-: Reference alkali hydrolysis ladder. BBD-XL 
lanes C: dPAGE-isolated BBD-XL. OH- Lanes: dPAGE-isolated BBD-Pt treated under alkali 
hydrolysis conditions for increasing amounts of time (see Materials and Method in Appendix A). 
Arrows indicate major (bold arrow, G9) and minor (faded arrow, G11) sites of platinum 
coordination.  
 
crosslinked species generated using the two-piece SBBD complex, the site equivalent to G9 was 
again identified as one major adduct site (Figure A.1, Appendix A). Using this SBBD construct,  
hydrolysis mapping also identified the site corresponding to G31 as the crosslinking partner on the 
other side of the internal loop (Figure A.2, Appendix A). The identification from dPAGE-
isolated products of the intrastrand crosslink in BBD and the analogous interstrand crosslink in 
the SBBD duplex strongly suggests that internal loop crosslinking is a major structural 
determinant for altered gel mobility upon platinum coordination to BBD. 
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Cisplatin-RNA Reaction Rates:  
      The in vivo relevance of cisplatin-RNA reactions, including the internal loop crosslinking 
reaction observed here, depends in part on their rates relative to adduct formation with DNA or 
other cellular targets.  In evaluating the reaction rates of cisplatin with the oligonucleotides of 
Figure 2.2a, kinetic studies were performed at 37 0C and in a background of 0.1 M NaNO3/1 mM 
Mg(NO3)2 in order to approximate cation competition in vivo. Nitrate salts were used instead of 
chloride salts to prevent bias of the observed reaction rates due to an increase in the cisplatin 
anation rate.31 Because the aquation of cisplatin has been shown to be the rate-limiting step for 
reactions with oligonucleotides under similar conditions, cisplatin was aquated by reaction with 
AgNO3 immediately before use.32 RNA concentrations of 0.1 µM and platinum concentrations of 
at least 125-fold excess were used to ensure pseudo-first order conditions for the reaction (Figure 
A.4, Appendix A).  Reaction products were analyzed following separation by dPAGE and 
autoradiography. Under these conditions, all data fit well to a single exponential function, 
indicating that a single rate-limiting step dominates the kinetics of product appearance in each 
case.  
In addition to monitoring internal crosslink formation in BBD, reactions of cisplatin with two 
related hairpin structures were monitored. RNA HP and DNA HP (Figure 2.2a) retain the 
flanking helical and terminal loop sequences of BBD, but replace the internal bulge region with a 
fully base-paired sequence. These hairpin constructs provide control sequences having similar 
base composition, length, and terminal loops to those of BBD. Reaction of aquated cisplatin with  
both HP constructs results in products that migrate more slowly, in contrast to the faster-
migrating crosslinked species produced with BBD (Figure 2.4a). As observed from Figures 2.4a 
and 2.4b, both RNA sequences (BBD and RNA HP) react at similar rates of kobs = 9.8(1.0) × 10-5 
and 8.3(2) × 10-5 s-1 respectively in 50 µM CP, pH 7.8 (Table A.1, Appendix A). Product 
formation for the DNA construct is 5-6 fold slower, with an observed rate constant of 1.7(2) ×10-5 
s-1 under identical conditions. The calculated second-order rate constants are krxn2 = 2.0(2), 1.7(3), 
and 0.33(3) M-1s-1 for BBD, RNA HP, and DNA HP respectively. Reaction rates were also 
investigated, under identical buffer conditions, for the two-stranded SBBD hybrid substrate for 
which product formation results in a clearly-separated crosslinked species (Figure 2.2c and A.3, 
Appendix A). For SBBD, a pseudo first-order rate constant of kobs= 5.2(3) × 10-5 s-1 and a 
calculated second-order rate constant of krxn2= 1.1(1) M-1 s-1 were obtained in 50 µM aquated 
cisplatin (Figure A.3 and Table A.1, Appendix A). These values are approximately 50% of 
those determined for BBD, but still reflect faster reaction rates than observed for the DNA HP.  A 
likely explanation for the slower reaction rate observed for intermolecular crosslinking of the  
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Figure 2.4. Platination kinetics. (a) Time-dependent product band appearance following 
treatment of radiolabeled RNA and DNA substrates with cisplatin and analysis by dPAGE. 
Oligonucleotide sequences are shown in Figure 2.2a. (b) Comparison of the reaction rates of 
cisplatin with BBD (open circles), RNA HP (filled circles), and DNA HP (triangles). Data are fit 
to a pseudo first-order rate expression as described in Materials and Methods, Appendix A. 
Conditions in (a): 0.1 µM oligonucleotide, 50 µM cisplatin, 100 mM NaNO3, 1 mM Mg(NO3)2, 
and 5 mM TEA (pH 7.8) at 37 °C.  
two-piece RNA SBBD construct in comparison with intramolecular crosslinking in BBD is the 
incomplete hybridization of the SBBD strands under these reaction conditions (see Materials 
and Methods, Appendix A). Nonetheless, the fact that similar values are observed for 
crosslinking in both BBD and the two-piece SBBD suggests that similar rate-limiting steps guide 
the internal loop crosslinking reaction regardless of RNA construct.   
The reactions of aquated cisplatin with BBD and SBBD are pH-dependent, increasing in rate 
as the pH is lowered. At pH 6.8, second-order rate constants of 8.5(7) and 6.8(2) M-1 s-1 are 
measured for BBD and SBBD, respectively (Table A.1, Appendix A, data not shown). Based on 
known protonation equilibria for aquated cisplatin species, this rate enhancement likely reflects 
protonation of a cisplatin hydroxide ligand to aqua ligand on platinum(II), and is a closer 
approximation to rates that might be expected for in vivo conditions.  
 
Analysis of Platinated RNAs by MALDI-MS:  
As described above, platination of the RNA and DNA domains used in this study results in 
products that have distinctly altered mobilities when analyzed by dPAGE. To further analyze 
these products, MALDI-MS was used to identify platinum-oligonucleotide species33 in samples 
isolated from the dPAGE gels. MALDI-MS data for the RNA and DNA HP sequences reacted for 
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5 hr at a ratio of 5:1 platinum:oligonucleotide are shown in Figure 5a. Products containing 
[Pt(NH3)2]2+ adducts appear at the oligonucleotide mass plus increments of 229 amu. Additional 
lower-intensity peaks are often present at ~+17, +23 and +39 amu that are ascribed to residual 
H2O/OH/NH4+, Na+, and K+, respectively.  These features appear in untreated RNA as well as 
platinated RNA and their presence along with the breadth of the features preclude identification 
of [Pt(NH3)2X] (X=H2O, OH-, or Cl-) species. Although MALDI MS is not precisely quantitative, 
comparison of relative intensities within identically treated samples provides qualitative 
information on relative populations of the major RNA-platinum adducts. The data in Figure 2.5 
show that RNA and DNA HP samples, treated under the reaction conditions described above, 
separate into upper and lower dPAGE bands that both contain platinated oligomers. As expected 
from their slower electrophoretic mobility, samples isolated from the upper band of these gels 
show a higher extent of platination.  At a ratio of 5:1 Pt:oligomer, species with 1-3 [Pt(NH3)2]2+ 
are present in the lowest-running dPAGE bands, whereas the higher bands contain oligomers with 
2-4 [Pt(NH3)2]2+ bound (Figure 2.5a). Consistent with the observation that RNA exhibits a faster 
reaction time, a higher population of the +4 [Pt(NH3)2]2+ species is observed for the RNA HP 
sample than is found for the DNA analogue at the same timepoint. Faster reaction kinetics with 
RNA are also evident from bulk analysis of samples that are reacted for 23 hr in the high 
platinum:oligonucleotide ratios used for kinetic studies. In this case, the bulk DNA HP sample 
shows an overall adduct distribution that has major populations of 2-3 bound [Pt(NH3)2]2+, 
distinctly fewer than the 5-6 [Pt(NH3)2]2+ in the highest amplitude MALDI-MS peaks for the 
RNA HP sample treated under identical conditions (Figure 2.5b). From these data, it is apparent 
that the cisplatin-treated HP products separated by dPAGE all contain multiple platinum adducts. 
In the case of the mainly helical hairpin samples, the major product quantified for kinetics 
analysis is separated as a lower-mobility species that also contains on average at least one more 
[Pt(NH3)2]2+ ion (Figure 2.5c). Although not a complete study, these data are broadly consistent 
with a model in which one site on the HP sequence both reacts more quickly with cisplatin, and 
also causes a conformational change resulting in a distinctly lower-mobility species. Slower 
platination reactions occur at other sites, creating products that are not clearly separated by these 
dPAGE conditions.    
The products of BBD platination were also analyzed by MALDI-MS.  If a similar model 
holds in which one faster-reacting site results in altered gel mobility, then for the BBD reactions 
it is predicted that the higher mobility, cross-linked products will also contain an additional 
[Pt(NH3)2]2+ ion.  An alternative model for reactions of platinum with the BBD sequence is that  
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Figure 2.5. MALDI-MS analysis of platinated oligonucleotides. (a) Positive-ion mode MALDI 
mass spectra of products following cisplatin treatment of the RNA HP and DNA HP and isolation 
via dPAGE. Product bands are labeled rHP-P1 and dHP-P1 for RNA HP (rHP), and DNA HP 
(dHP) respectively. (b) Positive-ion mode MALDI mass spectra of the products of 23 hr reactions 
of RNA HP and DNA HP with cisplatin under the reaction conditions used for Figure 2.3. (c) The 
photograph and subsequent MALDI of the two main electrophoretic bands resulting from 
cisplatin treatment of LSBBD (sequence in Figure 2.2). The LSBBD (LS) product band is labeled 
LS-XL. Conditions: (a) Reactions were performed with 30 µM oligonucleotide, 150 µM cisplatin, 
100 mM NaNO3, 1 mM Mg(NO3)2, and 5 mM MOPS (pH 6.8) at 37 °C for 5 hr. The bands were 
separated by 20% dPAGE, stained with methylene blue, and then excised. MALDI-MS was 
performed in 3-hydroxypicolinic acid as a matrix. (c) Same as in (a), except that the reaction 
contained 90 µM cisplatin. 
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the crosslinking and non-crosslinking sites react at equal rates, which would result in an equal 
distribution of platinum in both dPAGE bands.  To simplify the MALDI-MS data, a modified 
BBD sequence that maintains the internal loop but reduces the number of other purine sites was  
employed (Figure 2.2a).  MALDI-MS spectra of platinated LSBBD shows that both dPAGE-
isolated products contain multiple platinum adducts, but that peaks from the faster migrating 
product band are indeed shifted by approximately +1 [Pt(NH3)2]2+ fragment (Figure 2.5c). 
Additional evidence that the gel bands observed for platinated BBD differ by one [Pt(NH3)2]2+ 
fragment is provided by the dependence of reaction rates on platinum concentration. With 
platinum in large excess, the observed reaction rates vary linearly with a slope of 1.1 (r2 = 1.0, 
Figure S2.4, Appendix), consistent with a 1:1 ratio between platinum and product. 
  
The Significance of Cisplatin Binding to RNA:  
Understanding of the biological roles of RNA has vastly expanded over the last three 
decades.34 RNA is now recognized to regulate transcription and translation through gene silencing 
and RNAi pathways,35.36 as well as through specific binding of small molecules in the structured 
regions of riboswitches.37-40 Intricate RNA structures support catalytic active sites,41 and dynamic 
RNA-protein rearrangements occur in complex cellular machineries such as the spliceosome.22 
These factors serve as the basis for the recent push in advancing RNA as a drug target and spur 
interest in understanding how existing nucleic acid-targeted drugs might act in previously 
unidentified pathways.45,46 Cisplatin provides an example of a known DNA-binding compound 
that might have unique interactions with complex RNA structures. Factors that may be relevant to 
structurally diverse RNAs have been encountered in studies of platinated DNA hairpins, 
platinum-crosslinked quadruplex structures, and platinated DNA-protein complexes.47-53 
Additionally, preliminary investigations have already begun to address cisplatin’s use as a 
structural probe and as drug conjugate for targeting RNA.15,17,54,55   
      This report describes cisplatin coordination to a 41-nucleotide RNA branch-bulge subdomain 
(BBD) that is derived from a U2-U6 snRNA complex proposed to form the active core of the 
spliceosome (Figure 2.1).23,24 Cisplatin-induced intramolecular crosslinking takes place between 
G bases located in opposing sides of the BBD internal loop. In a cellular context, crosslinking of 
this type could be imagined to disrupt binding of the branch oligonucleotide or dissociation of the 
U2:U6 complex. It is interesting to note that the 3’ side of the BBD internal loop corresponds to 
an invariant region of the U6 snRNA that is hypothesized to contain essential metal binding sites 
in the biological complex.56,57 The ability of cisplatin to compete for pre-organized metal bind 
sites in RNA is unestablished and presents an interesting possibility for predicting in vivo drug 
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binding locations. Further studies will also focus on the sequence requirements and generality of 
cisplatin-based drug interactions with structured RNAs.  Initial experiments indicate that this 
crosslinking reaction is tolerant of single base substitutions in the BBD internal loop, but that 
substitution of G31, the 3’ partner in the major crosslink, with non metal-coordinating U results 
in a slightly different product as reflected by altered mapping data (data not shown).   These 
limited studies indicate that platinum-induced crosslink formation is not strictly limited to internal 
loops with this exact BBD sequence, and is likely to take place in other structured RNAs.  In 
general, cisplatin crosslinks in functional RNAs could disrupt a host of cellular processes that rely 
on RNA’s dynamic structure.  
Drug-binding kinetics may be an important factor governing the significance of cisplatin-
RNA adducts in vivo. In this report we chose to compare the reaction rates of similar RNA and 
DNA oligomers in vitro in order to begin to address this question. Somewhat surprisingly, the 
RNA constructs exhibit reaction rates that are 5-6 times faster than those measured for the DNA 
construct. In a related study, Elmroth and coworkers observed faster binding by other 
platinum(II) compounds to a 13-nt RNA hairpin in comparison with its DNA analogue.  Although 
that study used different reaction conditions than employed here, most notably lower ionic 
strength, the reported rate constants are within an order of magnitude of those in Table A.1, 
Appendix A.12 Combined, these observations support RNA as a kinetically competitive target for 
cisplatin. 
The application of polyelectrolyte theory to the platination of RNA or DNA suggests a model 
involving entry of a charged platinum species into the condensed cation atmosphere of a nucleic 
acid, followed by irreversible monoadduct and diadduct formation.12,58-60 The range of literature 
values for the rate of monoadduct formation on duplex DNA by [Pt(NH3)2Cl(OH2)]+ vary from 
~0.1-1 M-1s-1.61-63 From this study, the calculated second order rate constant for the platination of 
the DNA HP is 0.33(3) M-1s-1 and lies within this range, while the rates observed for the RNA 
constructs are somewhat faster at ~2 M-1s-1 (Table A.1, Appendix A). The observation that 
similar rates are obtained for monoadduct formation on two structurally distinct RNAs indicates 
that broader factors such as electrostatic potential and oligomer flexibility likely dictate enhanced 
reactivity when compared with DNA.  Individual contributions of these factors are currently 
under investigation. 
MALDI-MS allows identification of nucleic acids with bound [Pt(NH3)2]2+ fragments33 and 
was used to analyze bulk reaction mixtures and dPAGE isolated oligomers in this study. MALDI-
MS analysis of platinated oligomers isolated from dPAGE shows an average of one additional 
[Pt(NH3)2]2+ fragment in the product bands.  This observation supports a model in which specific 
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sites within each oligomer react quickly with cisplatin and are responsible for the structural 
distortions leading to altered gel mobility. Previous observations of kinetically preferred sites for 
platinum adduct formation on DNA have been reported.  Enhanced reactivity can be based on 
electronegativity and target site geometry, as influenced by the nucleotide identity as well as 
oligonucleotide length, and secondary and tertiary structure.49.53.64-71 Particularly relevant to this 
study is the observation of cross-strand adduct formation by [Pt(NH3)2(OH2)2]2+ in telomeric 
DNA model sequences.48,53 An even greater variety of platinum adducts might be expected for 
RNA based on its structural diversity and ability to specifically chelate divalent metals.18-20  
The biological lifetime of each nucleic acid is an important factor in translating the faster in 
vitro rates observed for RNA in this study into a cellular context. In normal human cells the most 
rapidly turned-over class of RNA is mRNA.  Median mRNA lifetimes in human cell lines have 
been reported to be ~10 hr, with a wide range of decay rates that vary by ~500-fold.72  Both tRNA 
and rRNAs have significantly slower turnover rates, and lifetimes predicted to be on the order of 
days for average adults.73 The lifetimes and abundance of cellular RNAs suggest that platinum 
drug binding could occur on a timescale that may affect RNA processes within treated cells.  The 
types of cellular RNAs that are sufficiently accessible for platinum adduct formation, and the 
range of cellular consequences that could result from cisplatin interactions with RNA, are topics 
that remain to be addressed.  
 
Summary and Bridge to Chapter III:  
       Chapter II describes the how Pt(II) complexes derived from cisplatin coordinate to a 
structured RNA that is derived the active site of the spliceosome, an incredibly complex cellular 
machine. The results of this study motivated us to broaden our investigations of how the 
platination of RNA may be tied to the drug’s activity. Along these lines, Chapter III describes 
how platinum adducts act to disrupt the activity of four different types of RNA processing 
enzymes.  
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CHAPTER III 
 
ENZYMATIC PROCESSING OF PLATINATED RNAS 
 
 
Introduction: 
     This chapter was coauthored by Prof. Dr. Victoria J. DeRose who guided experimentation, 
contributed many meaningful ideas and co-wrote the corresponding manuscript. This chapter 
includes work published in the Journal of the American Chemical Society (2010, 132, 1946-1952, 
© 2010 American Chemical Society).   
 
Cisplatin and RNA Processing: 
      Cisplatin, cis-diamminedichloroplatinum(II), is broadly employed in the treatment of many 
cancers and is frequently used as a model for the development of nucleic acid targeted anti-tumor 
complexes. Years of extensive study have provided evidence that cisplatin’s activity stems from 
drug binding to neighboring purine nucleotides in sequences of genomic DNA, inducing 
structural distortions.1-3 Cellular proteins that recognize these distortions start a cascade of events, 
ultimately resulting in apoptosis.4-6 Despite RNA’s chemical similarity to DNA and a growing 
appreciation of the cellular resources devoted to producing, maintaining, and regulating the 
transcriptome,7-10 relatively little is known about how cisplatin affects biological processes 
involving RNA.   
      Previous reports have described the disruption by cisplatin of translation11 and splicing12 in 
cell extracts. These results are complemented by in vitro studies describing RNA oligonucleotide 
targeting by cisplatin13-18 and by several Pt-drug conjugates.19,20 In addition to these studies, our 
lab has recently reported that cisplatin is capable of crosslinking structurally complex RNAs.21 
Elmroth and co-workers18 and our laboratory21 have reported that in vitro, RNA binding is 
kinetically preferred over drug coordination to DNA. Taken together these initial findings raise 
important questions regarding which types of cellular RNAs may be targeted by cisplatin, and 
whether cellular RNA function is significantly impaired as a result.  
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      In RNA life cycles, a number of enzymes carry out the chemical reactions required to 
produce, regulate, and recycle the transcriptome.7,8,10,22 Because RNA-protein interactions are 
sensitive to RNA structure, we hypothesized that platinum binding to RNA would disrupt the 
function of enzymes that process RNA.  In this chapter we determined how RNA processing by 
5’à3’ and 3’à5’ exonucleases, a purine-specific endoribonuclease, and a reverse transcriptase 
are affected by cisplatin-RNA adducts in vitro.  Each of these enzymes is inhibited at the site of a 
Pt(II)-RNA adduct, but with slightly different products that depend on the adduct and the enzyme. 
This enzymatic inhibition likely results from a combination of nucleobase modification and more 
general structural distortions caused by platinum binding.  Additionally, we have examined the 
reaction of platinated RNAs with thiourea and report that cisplatin-RNA adducts are reversed by 
prolonged incubation, providing an experimental means to address future biological queries 
requiring platinum removal from RNA. 
 
Inhibition of Exonuclease Activity by Platinum(II)-RNA Adducts:  
      Because RNA damage and mis-processing are increasingly implicated in disease 
mechanisms,23-25 it is of interest to investigate the mechanisms by which platination of RNA may 
be capable of disrupting the dynamic function of the transcriptome. Exonucleases, specifically 
directional phosphodiesterases, have been previously shown to stop at metallated DNA 
sequences.26 Exonucleolytic cleavage by both the 3’à5’ phosphodiesterase from Croatalus 
adamanteus (VPD, Phosphodiesterase I) and the 5’à3’ phosphodiesterase from bovine spleen 
(SPD, Phosphodiesterase II) is blocked by binding of Pt and Rh complexes to DNA 
nucleobases.27-33 The RNA transcriptome requires the function of many exonucleases that act in 
RNA maturation and degradation processes and facilitate post-transcriptional control of gene 
expression.22,34 Examples of important, directional cellular RNA exonucleases include Xrn1 
(5’à3’) and components of the exosome complex (3’à5’).35  mRNA turnover by these enzymes 
is highly dependent on RNA stability elements such as 5’- m7-G caps, 3’-poly(A) tails,35 and 
stable secondary structures.36 RNA platination may also inhibit or alter exonuclease activity, 
affecting RNA processing pathways.  
      VPD and SPD exonucleases have been used previously to locate transplatin crosslinks in 
RNA duplexes,37 and to identify the binding locations of platinum complexes in 4-mer GA3 
RNAs.38 In these experiments, exonuclease digestion proceeds up to nucleotides involved in 
platinum binding, producing RNA fragments that retain bound metals. We systematically tested 
whether similar enzymatic inhibition resulted from cisplatin binding to single-stranded 13-mer 
RNAs containing isolated purine sequences that are known to be targeted by cisplatin. In these  
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Table 3.1. Products from the enzymatic processing of 13-mer RNAs. a VPD: 3′à5′ Venom 
Phosphodiesterase. b SPD: 5′à3′ Spleen Phosphodiesterase. c U2: RNase U2, cleaves 3′ to A or G. 
d “Pt” indicates[Pt(NH3)2]. “X” indicates no observed products. 
 
experiments, reaction of 5’-(U)6-XY-(U)5 (XY = GG, AG, GA, or GU) RNAs with an aquated 
form of cisplatin produced a dominant product containing a single [Pt(NH3)2] fragment when 
analyzed by MALDI-MS (Figures 3.1a and 3.1b, as well as B.1 and B.3-B.6, Appendix B).21 
Peaks from platinated RNAs display masses corresponding to the parent RNA plus 227 amu, 
depicting two less H’s than would be expected from attachment of a Pt(NH3)2 fragment (229 
amu). This is due to the proton transfers necessary to offset binding of Pt2+ and still produce 
singly charged molecular ions.39 Platinated RNAs were subsequently digested using VPD and 
SPD exonucleases, after which MALDI-MS was used to characterize the products of each 
reaction. The results of these experiments are summarized in Table 3.1.  Spectra corresponding to 
each entry are included as Supplementary Information, Figures B.3-B.6 in Appendix B.  
      In all cases VPD (3’à5’) digestion of platinated RNAs containing two neighboring internal 
purines extends up to, but not beyond the 3’ purine (Figure 3.1c and Table 3.1). These results 
correspond well with previous experiments using DNA, where metallation is presumed to alter 
DNA structure and disrupt enzyme recognition, protecting an oligonucleotide from further 
digestion.40,41 VPD digestion of the platinated RNA strand containing a single G reproducibly 
gives [UUUUUUG + Pt(NH3)2 +H]+ as the major detected product, as expected for  
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Figure 3.1. Platination and 3’à5’ exonuclease digestion of RNAs.  MALDI-MS spectra of (a) 
5’-(U)6-AG-(U)5-3’ RNA, (b) platinated 5’-(U)6-AG-(U)5-3’ RNA, (c) platinated 5’-(U)6-AG-
(U)5-3’ RNA digested by VPD (3’à5’) exonuclease, and (d) platinated 5’-(U)6-GU-(U)5-3’ RNA 
digested by VPD (3’à5’) exonuclease. 
 
monofunctional adducts forming at the single G.  Interestingly, a major secondary peak 
representing [UUUUUUGU + Pt(NH3)2 + H]+ RNA fragment is also detected (Figure 3.1d). The 
differences between these products and those obtained from digestion of the platinated XY= GA, 
AG, and GG RNAs presumably reflects differential processing of mono- versus difunctional 
platinum adducts. A detailed examination of MALDI-MS spectra obtained from the platinated 5’-
(U)6-GU-(U)5 RNA, however, does not show masses for an additional Cl, H2O, or OH platinum 
ligand as expected to be present in a monofunctional adduct (Figure B.1, Appendix B). Although 
we suspect that this ligand may be lost during ionization processes,42,43 it is also possible that the 
fourth Pt(II) coordination site is occupied by an RNA ligand, perhaps by a neighboring U 
nucleobase. In biologically relevant pH ranges, the potential N3 amine ligands in uridine (and 
thymidine) nucleobases are not typically considered to be targets for cisplatin because they are 
protonated at pH values below 10.44 Platination of thymine and uracil have, however, both been 
observed.45,46 In addition, characterization of a platinated d(TpG) DNA dinucleotide by NMR 
spectroscopy found evidence for solvent-dependent Pt(II) coordination to either the N3 of a 
neighboring pyrimidine base in aqueous solution,47 or alternatively, interaction with non-bridging 
oxygens in the phosphodiester backbone in less polar solvents.48 The multiple products resulting  
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Figure 3.2. 5’à3’ digestion of platinated RNAs. MALDI-MS spectra of (a) SPD (5’à3’) 
digestion of platinated 5’-(U)6-AG-(U)5-3’ RNA and (b) SPD (5’à3’) digestion of platinated 5’-
(U)6-GU-(U)5-3’ RNA. 
 
from nuclease digestion of the platinated 5’-(U)6-GU-(U)5 RNA may reflect a combination of 
these types of Pt(II) interactions. Digestion of the same singly platinated RNAs using SPD 
(5’à3’) also shows that this exonuclease is inhibited at platinated RNA sequences. For RNAs 
containing two internal purines, SPD digestion stops at the 5’U that precedes each predicted 
platinum adduct (Figure 3.2a and Figures B.3-B.6, Appendix B).  These results, and similar 
observations by Chottard and coworkers,34 contrast with what is typically observed for cisplatin 
diadducts occurring with DNA, where SPD cleavage proceeds all the way up to a platinum 
binding site.40,41 In addition, it is again found that the platinum adducts formed with the 5’-(U)6-
GU-(U)5 RNA disrupt exonuclease activity differently than platinum adducts formed with the 
XY= GA, AG, and GG RNAs. SPD digestion of the platinated XY= GU RNA, produces 
[GUUUUU + Pt + H]+ and [UGUUUUUU + Pt + H]+ RNA fragments (Figure 3.2b). As with 
VPD digestion, the presence of multiple digestion products may reflect different types of 
platinum coordination occurring at this site. One model explaining the variances observed in how 
both VPD and SPD process different types of platinum adducts is that each type of adduct 
uniquely alters RNA structure. Platinum coordination to a single nucleobase is expected to cause 
less distortion in the phosphodiester backbone of an RNA than that resulting from platinum 
chelation. While cisplatin broadly disrupts exonuclease processing, these results show that the 
precise outcome of this inhibition relies on both the type of platinum adduct formed with an RNA 
and on how a given protein recognizes specific aspects of RNA structure.  
     Cellular 5’à3’ and 3’à5’ exonucleases often act concertedly to degrade RNAs and have 
synergistic responsibilities in RNA processing.35 For this reason a single platinum adduct 
occurring on an RNA may eventually be approached by nucleases from each direction. Prolonged 
incubation of the platinated RNAs used in this study with both 3’à5’ and 5’à3’ exonucleases  
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results in low molecular weight products of only a few nucleotides in length (data not shown).  In 
some cases, these products may represent the end of a drug-damaged RNA’s cellular lifecycle.  
 
Influence of Platinum(II)-RNA Adducts on RNA Processing by RNase U2:  
      In addition to exonucleases, a number of sequence- and structure-specific endoribonucleases 
(RNases) are used to trim and modify RNAs in a cell. RNases such as RNase P and Drosha 
(RNase III) are critical in maturation of the transcriptome.49,50 New evidence showing that certain 
RNases are active in cellular stress response51 suggests that if platination is capable of disrupting 
RNase function, cells may then become handicapped in their ability to respond to platinum 
damage. 
     RNases T1 and U2 specifically recognize purine ribonucleotides and catalyze cleavage of the 
3’ phosphodiester bond attached to a G or an A.52,53 Monofunctional [Pt(NH3)3Cl]+ coordination 
to the N7 atom of purine nucleobases has been shown to disrupt molecular recognition by RNase 
T1 and RNase U2.54 Cleavage patterns produced by partial RNase T1 digestion have been used in 
several studies in order to infer platination sites and monitor broad structural changes in RNA  
 
Figure 3.3. RNase U2 processing of platinated RNAs. MALDI-MS spectra obtained following 
(a) RNase U2 digestion of 5’-(U)6-GU-(U)5-3’ RNA, (b) RNase U2 digestion of platinated 5’-
(U)6-GU-(U)5-3’ RNA, (c) RNase U2 digestion of 5’-(U)6-GA-(U)5-3’ RNA, and (d) RNase U2 
digestion of platinated 5’-(U)6-GA-(U)5-3’ RNA. 
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resulting from platination.16-18 Our findings using processive exonucleases led us to investigate 
whether endonucleolytic cleavage was similarly dependent on the type of platinum adduct formed 
or dependent upon additional factors such as RNA sequence. To test this, platinated 13-mer 
RNAs were reacted with RNase U2 (under conditions that cleave 3’ both A and G), and digestion 
products were again characterized by MALDI-MS.  For platinated sequences containing XY=GG, 
AG, and GU, RNase U2 cleavage is not observed, being blocked at the purine nucleotides 
predicted to be involved in platinum binding (Figure 3.3a and b).  Surprisingly, however, 
digestion of the platinated 5’-(U)6-GA-(U)5-3’ RNA shows a reaction product corresponding to 
[UUUUUUGA + Pt(NH3)2 + H],+ depicting RNase cleavage 3’ to an adenosine predicted to be 
involved in a cisplatin diadduct (Figure 3.3c and d).  In DNA, closure of monofunctional 5’-
d(AG*)-3’ cisplatin adducts is preferred over closure of 5’-d(G*A)-3’ adducts,55 raising the 
possibility that cisplatin does not readily form a diadduct with the GA-containing RNA.  
However, data obtained from VPD (3’à5’) digestion of the same platinated 5’-(U)6-GA-(U)5-3’ 
RNA (Figure B.2, Appendix B) shows no digestion beyond the 3’ adenosine, supporting its 
involvement in a cisplatin diadduct. These cumulative data suggest that the platinated G*A* RNA 
adduct is uniquely recognized and processed by RNase U2, whereas other purine-Pt(II) adducts 
are not. The basis for this selectivity may arise from the RNase’s known A>G preference, 
allowing the endonuclease in some cases to partially recognize the 3’ platinated A despite 
platinum modification. Together, the inhibition of both 5’à3’ and 3’à5’ exonucleases and an 
endoribonuclease show that cisplatin-RNA adducts disrupt a representative of each of the 3 major 
classes of intracellular RNA-degrading enzymes22 and suggests that platination may disrupt RNA 
processing reactions in drug-treated cells. 
 
Platinum(II)-RNA Adducts Disrupt cDNA Synthesis:  
      Accessing the information stored within an RNA transcript typically relies on successful 
recognition of an RNA sequence through the formation of Watson-Crick base pairs.  In addition 
to processes such as si- and miRNA genetic regulation that rely on sequence complementarity in 
trans, cellular machines such as the ribosome and reverse transcriptases (RTs) move over long 
sequences of RNA where even relatively infrequent platination could potentially stall or 
otherwise disrupt function. Correspondingly, reverse transcription is commonly used to study 
both natural (e.g. hypermodified nucleobases such as wybutosine) and unnatural (e.g. 2’-OH 
acylation used in SHAPE chemistry) RNA modifications,56,57 making it a technique amenable to 
monitor platination of RNA. Recently Rijal, and Chow have reported that cisplatin binding to 
exposed purines in the E. coli ribosome may be studied by RT-based primer extension of RNA  
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Figure 3.4. Reverse transcription of platinated PEBBD. a) Sequence of the BBD region of 
PEBBD.  5’ and 3’ sequences attached for in vitro PCR amplification of coding DNA, 
transcription, and reverse transcription are represented by blue lines.  RT stops are represented by 
green arrows. b) Reverse transcription of platinated PEBBD analyzed by 15% sequencing 
dPAGE along with a plot of band intensities quantified using ImageQuant software. 
 
isolated from drug-treated cells.15  We extended this methodology to locate platinum adducts with 
an RNA termed PEBBD (Primer-Extended BBD) (Figure 3.4a). We have recently reported that  
the internal loop contained in the PEBBD sequence forms intramolecular crosslinks when reacted 
with cisplatin.21 To explore the ability of Pt(II) adducts to affect RT-based primer extension, 
PEBBD RNA was reacted with increasing amounts of an aquated form of cisplatin, annealed to a 
5’ end-labeled DNA primer and reverse transcribed using M-MuLV RT.  Primer extension was 
monitored using sequencing dPAGE (Figure 3.4b).  cDNA synthesis proceeds 5’à3’ (toward the 
5’ end of the RNA), and shows several platinum-concentration dependent disruptions. The first 
major disruption of RT at A32 occurs immediately 3’ to a G that we identified previously, using 
chemical footprinting, to be involved in platinum crosslinking across the internal loop of this 
RNA.21 A second major interruption (A26) is observed immediately prior to a GG sequence 
adjacent to a capping GAAA tetraloop, indicating platination at this site. Additional RT stops in 
the GAAA tetraloop may indicate platinum binding to this region of PEBBD.  Tetraloops of the 
general GNRA sequence are highly conserved RNA structural motifs and have been predicted to 
contain metal-binding sites.58-60 It is interesting to postulate that RT inhibition in this region  
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Figure 3.5 Reversal of platinum(II)-RNA adducts using thiourea. MALDI-MS spectra of the 
reaction of platinated 5’-(U)6-GG-(U)5-3’ RNA with thiourea taken over the course of 72 h. 
Similar results are observed with a platinated 5’-(U)6-GU-(U)5-3’ RNA (data not shown). 
 
results from cisplatin targeting of this semi-“native” metal ion-binding site.  Information from 
nucleotides on the 5’ side of the internal loop is obscured by platinum-independent inhibition 
under these RT conditions, perhaps due to formation of stable secondary structures with 
remaining regions of the 5’ primer sequence.15 These data suggest that reverse transcription is 
broadly applicable to the identification of platinated sites in RNA, and further suggest that 
platination could disrupt similar enzymatic processing events requiring RNA recognition in vivo.  
 
Reversal of Platinum(II)-RNA Adducts Using Thiourea:  
     The removal of cisplatin adducts from DNA through reaction with sulfur-containing small 
molecules has been studied pursuant to an understanding of how biomolecular thiol and 
thioketonethioketone nucleophiles might compete for cisplatin binding or remove drug adducts in 
the cell.61 Additionally, platinum removal is a necessary step in several common experimental 
methods used to study cisplatin binding to DNA, and S-donors provide a milder alternative to the 
reaction conditions required for more commonly used cyanide salts.26,62,63 We therefore studied 
the reaction of thiourea with platinated RNAs, using MALDI-MS to monitor the disappearance of 
platinated 5’-(U)6-GU-(U)5-3’and 5’-(U)6-GG-(U)5-3’ RNAs.  When a 200 µM solution of 
platinated RNA is reacted with an equal volume of a saturated thiourea solution at 37 ºC, 
products corresponding to platinated RNAs disappear while products representing un-modified 
RNAs increase in relative abundance (Figure 3.5). While MALDI-MS is not strictly a 
quantitative technique and therefore cannot be used to assess the kinetics of the platinum 
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removal, the spectra indicate the complete disappearance of platinated RNAs at 72 h under these 
conditions with no detectable degradation of the RNA. This reaction should be amenable to future 
studies seeking to remove cisplatin from pools of RNA isolated from drug-treated cells, and 
suggests that sulfur containing biomolecules have the potential to reverse cisplatin-RNA adducts. 
 
Platination of RNA Generally Disrupts RNA Processing: 
     The results of these experiments demonstrate that single [Pt(NH3)2] adducts in an RNA 
oligonucleotide inhibit exonuclease, endonuclease, and reverse-transcription activities in a 
sequence-specific manner.  Combined, these results show that platination of RNA disrupts the 
function of a number of enzymes that are analogous to those necessary for proper function of the 
transcriptome.  Successful RNA maturation, splicing, regulation, translation, and degradation are 
all reliant upon the chemical fidelity of RNA transcripts. Platinum modification of individual 
nucleobases or more general alterations in RNA tertiary structure resulting from treatment with 
Pt(II) compounds may disrupt these critical processes in vivo. In the complex environment of a 
cell, additional factors may influence the processing of platinated RNAs, such as recently 
discovered RNA surveillance mechanisms responsible for handling RNA damaged by oxidative 
stress.25,62 Taken together, these results drive interest in new studies that seek to deconvolute the 
effects of RNA platination from other cell-wide responses. 
 
Summary and Bridge to Chapter IV: 
     Chapter III describes how Pt(II) coordination to an RNA interferes with enzyme recognition 
and coupled functions, leading us to suggest that such disruption could take place in drug-treated 
cells. Having learned that thiourea could reverse Pt(II) adducts formed on RNA we became 
interested in the reaction of Pt(II) compounds with RNAs that contained synthetically installed S 
substitutions at specific positions along the phosphodiester backbone. Chapter IV describes our 
success in engineering a new RNA-RNA crosslinking method based on Pt(II) targeting of such 
substitutions. 
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CHAPTER IV 
 
SITE-SPECIFIC PLATINUM(II) CROSSLINKING IN A RIBOZYME ACTIVE SITE 
 
 
Introduction: 
     This chapter was coauthored by Prof. Dr. Victoria J. DeRose, who originally suggested that 
we pursue this interesting line of research. She guided experimentation, contributed many 
meaningful ideas and co-wrote the corresponding manuscript which is now under consideration 
for publication in The Journal of the American Chemical Society. 
 
Engineering an RNA Crosslinking Strategy:  
     Complex RNA structures are involved in an expanding list of important biological 
processes.1,2 The incorporation of site-specific crosslinking probes has proven to be a powerful 
means by which to study the often intricately folded architectures of these RNAs.3 Extending 
reports utilizing the nucleic acid coordination properties of Pt(II) complexes4 to probe DNA and 
RNA conformation,5-7 solvent exposure of nucleotides within the ribosome,8 and biomolecular 
contacts made in ribonucleprotein (RNP) complexes,9-11 we have engineered a new site-specific 
RNA-RNA crosslinking strategy based on Pt(II) targeting of phosphorothioate substitutions. In 
this strategy Pt(II) complexes are kinetically recruited12-15 and anchored to phosphorothioate 
substitutions embedded within an RNA. A second Pt(II) coordination site can then form 
crosslinks16-19 to other nearby nucleotides (Scheme 4.1). Here we describe the surprising 
selectivity of Pt(II) crosslinks formed within the catalytic core of the Hammerhead ribozyme 
(HHrz). 
  
“Hooking” the Hammerhead Ribozyme 
     The HHrz forms a 3-helix junction RNA motif with a complex core architecture that catalyzes 
a site-specific phosphorotransesterification reaction.20.21 HHrz catalysis has been proposed to 
involve coordination of a divalent metal to the pro-(R) non-bridging oxygen of the phosphodiester  
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Scheme 4.1. Platinum(II)-phosphorothioate RNA crosslinking.  
 
bond at the C17-C1.1 linkage that is cleaved during ribozyme-mediated catalysis (Figure 4.1).20-
22 We were optimistic that a Pt(II) probe might mimic such a metal and covalently capture RNA 
nucleophiles capable of acting as ligands for a metal bound to this site. Crosslinking studies were 
carried out using a two-stranded HHrz construct comprised of an “enzyme“ strand (HHrzES) and 
a non-cleavable, phosphorothioate-substituted “substrate” strand. Platination of phosphorothioate 
substitutions installed adjacent to ribonucleotides resulted in surprisingly high levels of RNA 
cleavage at these locations (data not shown). Studies involving a model RNA construct were used 
to demonstrate that Pt(II) coordination to a phosphorothioate sulfur atom is capable of inducing 
site-specific RNA cleavage (Figure C.3, Appendix C) over the time course of these experiments, 
prompting the concomitant use of deoxyribonucleotides with phosphorothioate substitutions 
(Scheme 4.1). 
      Crosslinking experiments were performed using the annealed HHrz reacted with three 
equivalents of cis-[Pt(NH3)2(OH2)Cl]+ under ionic conditions that support tertiary folding of the 
ribozyme (1 mM Mg2+, 100 mM Na+).23 This resulted in the formation of interstrand crosslinks, 
indicated by the formation of high molecular-weight products observed in dPAGE experiments 
(Figure 4.1). Importantly, crosslinking was not observed between the HHrzES and an unmodified 
substrate strand, SS(dC17), demonstrating the requirement for an embedded phosphorothioate to 
form intermolecular crosslinks. The C1.1 crosslinking site was further confirmed to be formed at 
the installed phosphorothioate through mild alkali hydrolysis mapping2,7 of the crosslinks formed 
using the 5’ end-labeled SS(dC17, C1.1ps) RNA (Figure C.1, Appendix C). In order to identify 
the nucleotide(s) trapped by the Pt(II) probe, crosslinks generated using the 5’ end-labeled 
HHrzES were similarly mapped. In this experiment a loss of hydrolysis products 3’ to U7 
indicates G8 as the major site of Pt(II)-induced crosslinking (Figure 4.2b). Presumably in the 
crosslinked HHrz, [Pt(NH3)2] is chelated between the C1.1 phosphorothioate substitution and the 
N7 atom of G8.24 Interestingly, increasingly strong hydrolysis treatment results in a second fall 
off in cleavage intensity following A9, indicating that in some cases, Pt(II)-crosslinking may also 
take place to the N7 atom of G10.1.  
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Figure 4.1. Pt(II)-induced crosslinking of the HHrzES-SS(dC17,C1.1ps) ribozyme. From left to 
right: (i) individual ribozyme components, (ii) the HHrzES-SS(dC17,C1.1ps) construct, (iii) a 
control HHrzES-SS(dC17) construct lacking a phosphorothioate linkage, and (iv) a docking 
deficient HHrz(Uloop)-SS(dC17, C1.1ps) construct. Conditions: 40 µM RNA in 1mM Mg(NO3)2, 
100 mM NaNO3, 10 mM Na2PO4, pH 7.0, 16 h, 37°C, analyzed by 20% dPAGE and stained with 
methylene blue.  
  
Crosslinking in a Target-Rich Coordination Environment 
     In order to better conceptualize structural features influencing the formation of Pt(II)-
phosphorothioate crosslinks, we used a HHrz crystal structure recently reported by Scott and 
coworkers25 to build in a [Pt(NH3)2(OH2)] fragment bound to either the Rp (Figure 4.3) or Sp 
(Figure C.2, Appendix C)  stereoisomer of a C1.1 phosphorothioate. Holding the RNA structure 
static, molecular mechanics calculations were used to minimize conformational strain and steric 
clash between Pt(II) probe and the RNA. Interestingly, the models obtained show the N7 atoms of 
several nucleobases located ~6.2-9 Å away directed toward the interior of the ribozyme’s active 
site and the Pt(II) probe. In this seemingly target-rich coordination environment, the specificity of 
crosslinking to the G8 position is somewhat remarkable. Crosslinking is expected to occur 
through an associative mechanism26 and may favor the N7 atom of G8 due to factors such as local 
structural dynamics and geometric alignment. In order to further investigate the influence of such 
factors we characterized HHrzES-SS(dC17, C1.1ps) crosslinking kinetics and tested the 
crosslinking efficiency of related RNA constructs.  
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Figure 4.2. Location of Pt(II) crosslinks formed in the HHrzES-SS(dC17, C1.1ps) ribozyme. a) 
Secondary structure of the HHrzES-SS(dC17, C1.1ps) ribozyme construct used in this work.21 b) 
Cleavage products produced by the alkali hydrolysis of Pt-crosslinked HHrzES-SS(dC17, C1.1ps) 
formed using 5’ end-labeled HHrzES. Control lanes: C: 5’ end-labeled HHrzES T1: G-specific 
sequence ladder generated by partial nuclease digestion with RNase T1 -OH: Reference alkali 
hydrolysis ladder. Platinum crosslinked lanes: C: dPAGE isolated, Pt-crosslinked HHrz-
SS(dC17, C1.1ps) –OH lanes: dPAGE isolated, Pt-crosslinked HHrz-SS(dC17, C1.1ps) treated 
using alkali hydrolysis conditions for increasing amounts of time. Yellow arrows designate 
platinum crosslinking sites. 
 
Rapid Crosslinking in a Ribozyme Active Site 
     Kinetics experiments were carried out using the 5’ end-labeled SS(dC17, C1.1ps) to monitor 
crosslink formation over times ranging from 1 to 8 h (Figure 4.3). Averaged over three 
experiments, crosslinking is observed to take place at a rate of 0.23 ± 0.02 min-1 (t1/2 ~ 10 min) 
with a calculated second order rate constant of 31 M-1 s-1. This rate constant is approximately 15-
fold higher than the ~2 M-1 s-1 rate constants observed for platination of unmodified hairpin-like  
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Figure 4.3. Crosslinking in the active site of the HHrz. (a) Crystal structure of the HHrz25 (pdb: 
2OEU) (b) Model of Pt(NH3)2(OH2) bound to the R stereoisomer of a C1.1 phosphorothioate built 
as described in Appendix C. The distance from Pt(II) to G8, the major site of PtII crosslinking, is 
indicated. Distances to other purine N7 sites are given in Figure S4.2, Appendix C.  
 
RNAs under identical conditions.7 An approximately 3-fold kinetic preference for Pt(II) 
coordination to phosphorothioate substitutions over equivalent GpG sequences has been reported 
in single stranded DNAs.14 Taken together, these data suggest Pt(II) coordination as the rate-
limiting step involved in HHrz crosslinking. In the HHrz, enhanced electrostatics are expected to 
further increase the rate of Pt(II)-complex formation. Extension of this model implies that Pt(II) 
crosslinking takes place rapidly following initial metal coordination and provides an upper limit 
for the lifetime of a RNA bound Pt(II) species of approximately 4 min. Dynamic rearrangements 
of RNA structure can occur on the micro- to millisecond timeframe27 making it difficult to obtain 
precise information regarding the folded state of the HHrz that gives rise to the observed 
crosslinks from these data alone. In order to experimentally address the tertiary organization 
necessary to crosslink the ribozyme we also characterized Pt(II) crosslinking using a docking-
deficient HHrz mutant. In the HHrz(Uloop) construct, replacement of the 5’-CAAAUA-3’ 
terminal loop with a series of U removes contacts required for accurate folding of the ribozyme 
and presumably organization of the molecule’s catalytic core.20,23a Platination of the 
HHrz(Uloop)-SS(dC17, C1.1ps) ribozyme results in a significantly less crosslink formation 
(Figure 4.1). This finding demonstrates that Pt(II) crosslinking in the core of the HHrz is 
dependent on accurate tertiary folding. 
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Figure 4.4. Rapid crosslinking of the HHrzES-SS(dC17, C1.1ps) ribozyme. a) Kinetic trace 
obtained for Pt(II)-crosslinking of the HHrzES-SS(dC17, C1.1ps) ribozyme using the conditions 
listed in Figure 1. b) Typical autoradiograph image obtained during kinetic studies.  
 
Structure-Dependent Crosslinking  
     We then sought to examine the range of structural contexts in which Pt-(II) phosphorothioate 
crosslinking could occur. Somewhat surprisingly, platination of an HHrz construct containing a 
phosphorothioate substitution at the C1.1-U1.2 linkage directly adjacent to the original 
C17,C1.1ps site did not result in intermolecular crosslinking (Figure C.4, Appendix C). In these 
experiments [Pt(NH3)2] coordination to the SS(dC17, U1.2ps) substrate strand was confirmed 
using MALDI-MS, suggesting that the lack of  crosslinking at this site was not due to a loss of 
Pt(II) coordination to the target phosphorothioate (data not shown).  Molecular modeling of the 
HHrz-SS(dC17, U1.2ps) construct indicates significantly larger distances to possible Pt(II)-
coordinating nucleobases (Figure C.2, Appendix C)  as well as the potential for a Pt(II) probe to 
form intramolecular adducts with the neighboring G1.3 nucleotide.24 Such coordination would act 
to preclude formation of intermolecular crosslinking in general and would limit the sequence 
contexts in which this crosslinking strategy could be employed. Control studies attempting to 
crosslink both SS(dC17, U2.1ps) and SS(dC17, U1.1ps) RNAs to a fully base-paired complement 
(Figure C.5, Appendix C) were unsuccessful.  
 
A Promising New Crosslinking Strategy 
     In summary we have presented a new RNA-RNA crosslinking strategy based on the targeting 
of a kinetically inert Pt(II) complex to a specific thio-substituted position within a structured 
RNA. Once anchored to this position the Pt(II) probe selectively crosslinks to nearby nucleotides. 
In this example we embedded a phosphorothioate substitution at the scissile phosphate of the 
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HHRz. Biochemical evidence indicates metal ion coordination to the C1.1 phosphodiester during 
the HHRz reaction,20-22 but current crystallographic models identify a Mn2+ atom coordinated to 
the G10.1 site25 (Figure 4.2). Under the conditions used in our experiments, G10.1 is the weaker 
of crosslinked species observed. The major crosslinking position, G8, is phylogenetically 
conserved, however mutational analyses of this position do not indicate direct participation by the 
G8 nucleobase in HHRz catalysis.20 The ability to use stereopure populations of phosphorothioate 
substituted RNAs30 along with isomeric Pt(II) complexes holds the potential to allow future 
investigations to be conducted at a more precise level. This technique may also be useful in 
identifying interacting structural domains in large RNA and RNP complexes, in particular 
because metal ions frequently mediate tertiary contacts in these RNAs. Preliminary studies 
demonstrating that Pt(II)-phosphorothioate crosslinks are reversible using thiourea11, 31 (Figure 
C.6, Appendix C) suggest that it may also be possible to adapt this crosslinking strategy to 
function in high-throughput contexts and add to the expanding repertoire of techniques being 
used  to probe the structure of the transciptome.32 
 
Summary and Bridge to Chapter V 
     Chapter IV describes the targeting of a Pt(II) complex to a phosphorothioate substitution 
embedded within the catalytic core of the Hammerhead ribozyme. Once Pt(II) is anchored to the 
phosphorothioate substitution, Pt(II) crosslinks form rapidly to nearby nucleotides with a 
surprising degree of structural selectivity. In the course of these experiments it was found that 
Pt(II) induced cleavage when coordinated to a phosphorothioate-substituted ribonucleotide 
containing a 2’-OH nucleophile. To investigate this metal-dependent activity we carried out the 
studies described in Chapter V which describes our efforts to understand fundamental details of 
Pt(II) coordination to phosphorothioate substitutions, namely, how Pt(II) is able to cleave, 
desulfurize, and isomerize phosphorothioate substituted RNAs.  
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CHAPTER V 
 
PLATINUM(II)-ACTIVATED CLEAVAGE, DESULFURIZATION AND 
ISOMERIZATION OF PHOSPHOROTHIOATE SUBSTITUTED RNAS 
 
Introduction: 
     This chapter contains contributions from Emma Downs, Josiah Vincek, Alex Kendall, and Dr. 
Victoria DeRose. Emma Downs performed NMR and MALDI-MS experiments characterizing 
Pt(II) coordination to the 5’-UpsU-3’ dinucleotide described in the text. Josiah Vincek obtained 
the majority of the MALDI-MS data as well as the kinetic traces presented in this study. Alex 
Kendall performed DFT calculations on Pt(II)-coordinated O,O’-diethylthiophosphate species, 
helped edit this chapter and continues to study this reaction. Dr. Victoria DeRose provided very 
helpful comments on the ideas presented in this chapter and edited it as part of its inclusion in this 
dissertation. I wrote this chapter, developed the mechanistic hypothesis presented within it, as 
well as assisted in and helped guide each line of experimentation.  
 
Platinum(II) Coordination to Phosphorothioates:  
 Nature relies on RNA to accurately transfer, regulate and transform genetic information.1-3 
RNA’s remarkable ability to catalyze many of the reactions involved in these processes using a 
limited set of nucleobase functionalities continues to raise fundamental questions regarding 
biocatalytic strategies.4 In many instances, complex tertiary folds position RNA nucleobases 
along with divalent metal ions with angstrom-level precision in order to activate specific 
phosphoryl transfer reactions.5-7 One powerful approach in characterizing the roles that metal ions 
play in the mechanisms of these reactions has been to install site-specific phosphorothioate (PS) 
substitutions.8,9 Substituting one of the non-bridging oxygens in the RNA phosphodiester 
backbone for a “softer”, more nucleophilic S atom can disrupt coordination to physiological 
metals such as Mg2+ and Ca2+ and facilitate interactions with softer metals such as Cd2+, 
producing diagnostic shifts in the metal ion requirements for RNA catalysis. These “thio 
effects”10 form the basis of classical metal ion “rescue” experiments.  
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    Despite the broad application of PS substitutions as mechanistic probes, relatively few 
studies have experimentally addressed soft metal ion coordination to the substitutions outside of 
the context of an RNA or protein active site. In previous work, Lönnberg and coworkers have 
described the metal-dependent reactivity of a PS linkage embedded within a 5’-UpsU-3’ construct 
(where “ps” is used to denote a 3’-5’ PS linkage between two nucleotides).11 In this study it is 
observed that hard metal ions (Mg2+, Gd3+) activate cleavage of the 5’-UpsU-3’ construct to a 
significantly lesser extent than they enhance cleavage of a non-substituted 5’-UpU-3’ analog 
containing a standard phosphodiester bond. The same hard metal ions are not observed to 
promote isomerization or desulfurization reactions. Contrasting this, thiophilic metal ions (Zn2+, 
Cd2+) are observed to increase the rate of 5’-UpsU-3’ cleavage well beyond the extent to which 
they promote cleavage of 5’-UpU-3’. In addition, Zn2+ promotes desulfurization as well as 
isomerization of the PS bond in 5’-UpsU-3’, producing both 3’-5’ and 2’-5’ phosphodiesters.  
Interestingly, the extent to which each metal ion promotes cleavage of 5’-UpsU-3’ correlates well 
with the stability of corresponding M2+-adenosine 5’-O-thiomonophosphate complexes  described  
by  Sigel   and  coworkers.12,13 These findings lead Lönnberg and coworkers to propose a 
mechanistic model in which hard metal ions coordinate primarily to the non-bridging oxygen of 
an installed PS, while softer metal ions prefer coordination to the S atom.11 Soft metal ion 
coordination is proposed to stabilize the dianionic thiophosphorane transition state common to 
each type of phosphoryl transfer reaction observed in this study. This stabilization is proposed to 
extend the lifetime of this species such that it may be considered a “borderline” intermediate 
rather than a transition state. Pseudorotation17 around this intermediate is proposed to give rise to 
the diverse (i.e cleaved, desulfurized, and isomerized) products observed in this study. The 
authors additionally suggest that a M2+-bound hydroxo ligand would conveniently fulfill the role 
of a general base in this reaction although they did not address this possibility experimentally. 
Such analysis would prove challenging as the metal ions studied in the report are kinetically 
labile, coordinating to the PS linkage only transiently.  
Here we report how Pt(II), a similarly soft metal ion, is able to activate cleavage of PS-
substituted RNAs in the absence of an RNA active site. In PS-containing oligonucleotide and 
small-molecule models, Pt(II)-catalyzed reactions also result in substantial amounts of 
desulfurization and isomerization, generating a mixture of 3’-5’ and 2’-5’ phosphodiesters in 
place of the original PS. Cumulatively, our data suggest a mechanism in which Pt(II) coordination 
to the PS sulfur atom withdraws electron density from the central phosphorous, activating it to 
nucleophilic attack from an adjacent and deprotonated 2’-OH (Scheme 5.1). Based on analogy to 
previous studies,11,15-17 we suggest that pseudorotation around a pentacoordinate phosphorane  
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Scheme 5.1. The reaction of Pt(II) complexes with phosphorothioate substitutions. a) Proposed 
reaction mechanism for [Pt(NH3)2XY]n+ (X,Y = OH2, -OH, -Cl) induced cleavage, desulfurization 
and isomerization of phosphorothioate substituted RNAs. The NH3 ligands of Pt are omitted for 
clarity. Axially and equatorial positions in the pentacoordinate phosphorane are indicated by “a” 
and “e” respectively. b) Hydrogen-bonding interactions predicted by molecular modeling of Pt(II) 
species coordinated to O,O’-diethylthiophosphate. 
 
intermediate is responsible for the variety of cleaved, desulfurized and isomerized RNA products 
that result from this reaction.  
     We initially became interested in Pt(II) coordination to PS substitutions during an effort to 
engineer a new RNA-RNA crosslinking strategy based on cis-[Pt(NH3)2(OH2)Cl]+ coordination to 
PS-substituted RNAs.18 In the course of these studies it was observed that when a PS substitution 
is installed 3’ to a ribonucleotide with a native 2’-OH, facile cleavage of this bond takes place 
following treatment with square planar Pt(II) complexes (data not shown).  The rate of this 
cleavage reaction in model oligonucleotides far exceeds that observed with similarly “soft” metal 
ion such as Cd2+, typically used in metal ion rescue experiments (equivalent conditions, Table 
D.1, Appendix D). In order to characterize this reaction we have pursued a series of MALDI-MS, 
31P NMR, and pH-dependent kinetic studies. Here we present these results which collectively 
suggest that a Pt(II)-coordinated hydroxo ligand is responsible for deprotonation of the ribose 2’-
OH that initiates this reaction (Scheme 5.1). Interestingly, the PS-coordinated Pt(II)-aqua species 
that result may also serve as general acids in several mechanistic pathways. Preliminary DFT 
studies portray electrophilic activation of the PS phosphorous atom and suggest a role for  
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Figure 5.1. Platinum(II)-promoted cleavage and desulfurization of PS-substituted RNAs. a) The 
sequence of the 10-mer RNA construct used in this work and the RNA products that result from 
reaction with Pt(II) complexes. The location of the PS substitution is highlighted in orange. 
Purple letters preceding each species correspond to labeling in the spectra and are used 
throughout the subsequent text and figures. b) MALDI-MS spectrum of unreacted 10-mer RNA. 
c) MALDI-MS spectrum of the products of the reaction after 4 hours. Conditions: 40µM RNA, 
120µM Pt(II), 1mM Mg(NO3)2, 100mM NaNO3, 10mM MES, pH 6.5, 37°C, 4 h. Reactions 
purified by C18 ZipTips and analyzed by positive ion mode MALDI-MS (see Materials and 
Methods, Appendix D). 
 
secondary H-bonding interactions by Pt(II)-coordinated ligands. Combined, these initial studies 
reflect the importance of several dynamic equilibria in the reaction of Pt(II) complexes with PS-
substituted RNAs. Additional experiments are proposed that would help characterize these 
equilibria and support our developing hypotheses. Increasing knowledge of metal ion-
phosphodiester/phosphorothioate chemistry may facilitate understanding how metal ions 
influence the reaction chemistry of these important types of chemical bonds both in vitro and in 
vivo. 
 
Reaction of Phosphorothioate-Substituted RNAs with Platinum(II) Complexes: 
In our initial studies, reaction of Pt(II) complexes with PS-substituted oligos whose sequences 
contained mixtures of A, C, G, and U nucleotides resulted in a surprising level of RNA cleavage 
at the location of the embedded PS (data not shown). Because Pt(II) complexes readily coordinate 
to A’s and G’s,19,20 potentially complicating efforts to characterize the cleavage reaction, further 
experiments employed a construct in which a single PS substitution was embedded within a 10-
mer RNA containing only C and U nucleotides not expected to coordinate to Pt(II) under the 
conditions used in this study (A, Figure 5.1a).  
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Solutions, of “aquated” Pt(II) species were prepared by reaction of cis-Pt(NH3)2Cl2 with 0.95 
equiv. of AgNO3. Due to competing equilibria21 a pH-dependent mixture of cis-[Pt(NH3)2XY]n+ 
(X,Y = OH2, -OH, -Cl) species are expected to result from this reaction. Based on preliminary 
195Pt NMR studies, [Pt(NH3)2Cl(OH2)]+ is the predominate species formed at pH 6.5 (Hostetter, 
DeRose unpublished).  This mixture of Pt(II) complexes was then reacted at a 3:1 Pt(II):RNA 
ratio with the PS-substituted 10-mer RNA (A) under ionic conditions used in previous studies 
with RNA (1mM Mg(NO3)2, 1mM NaNO3, 10mM MES, pH 6.5).18 Nitrate salts were used in 
these experiments to prevent the formation of Pt(II)-Cl species. Reaction products were 
subsequently characterized by MALDI-MS. In the resulting spectra three to five major species are 
observed depending on the extent of the reaction. These are: A) unreacted starting material (m/z= 
3012); B) Pt(NH3)- and Pt(NH3)2-bound 10mer RNA (m/z= 3223 and m/z= 3240 respectively); C) 
desulfurized 10-mer RNA (m/z= 2996); D) 5’-UUUUC>p-3’ (m/z= 1529, where “>p” indicates a 
2’-3’ cyclic phosphate); and E) 5’-CUUUU-3’ RNA (m/z= 1467) (Scheme 5.1, Figure 5.1b and 
c). D and E represent products resulting from cleavage at the site of the PS linkage. 
      The presence of a cyclic phosphate on the fragment of RNA corresponding to the 5’ half of 
10-mer used in these experiments (D) suggested that Pt(II) coordination to the PS substitution 
could activate intramolecular attack of the 2’-OH adjacent to the installed substitution, resulting 
in both cleaved products D and E. The additional presence of desulfurized, full-length products 
(C) parallels previous observations by Lönnberg and coworkers in similar experiments, who 
hypothesized that pseudorotation of a metal-coordinated phosphorane intermediate gives rise to 
desulfurized and isomerized products.11 The observation of Pt(II)-coordinated intermediates in 
our studies suggested the opportunity to build on the hypotheses presented by these authors.  
 
Verification of 3’-5’ to 2’-5’ Isomerization During Desulfurization: 
     An important caveat to early MALDI-MS studies was that this technique did not provide 
direct evidence that isomerization from a 3’-5’ to 2’-5’ linkage accompanied desulfurization. The 
16 amu mass difference observed between the parent RNA (A) and desulfurized products (C) 
simply depicts exchange of a S atom for an O atom (16 amu net mass difference). In order to 
establish that isomerization was simultaneously occurring, 31P NMR experiments were pursued. 
In these experiments a 5’-UpsU-3’ construct (identical to the one employed by Lönnberg and 
coworkers11) was treated with 1.5 equiv. of activated Pt(II) complexes and followed over times 
ranging from 1 to 3 days (Figure 5.2a).  Initially, two peaks corresponding to PS-substituted R 
and S stereoisomers appear at ~56 ppm (the R steroisomer expected to be further downfield based 
on previous observations,22,23 Figure 5.2b). At 24 hrs following platination additional peaks  
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Figure 5.2 31P NMR spectra obtained following the reaction of 5’-UpsU-3’ with activated Pt(II) 
complexes. Conditions: 1mM 5’-UpsU-3’, 1.5 mM Pt(II), 100 mM NaNO3, 1mM Mg(NO3)2, 10 
mM HEPES, pH 7.5, 25°C. a) 31P NMR spectra over the course of the reaction with the chemical 
species corresponding to each peak indicated. b) Enlargement of the spectral region 
corresponding to the phosphothioate diastereomers. c) Enlargement of the spectral region 
corresponding to 2’-5’ and 3’-5’ phosphodiesters.  
 
appear corresponding to both 3’-5’ and 2’-5’ phosphodiesters (~0 ppm, Figure 5.2c) and a cyclic 
phosphate (~19.8 ppm). At longer time points an additional peak appears that is tentatively 
assigned to a Pt(II)-coordinated PS (~25.8 ppm) based on previous observations of upfield shifts  
following Cd2+ coordination to a PS substitution.22 The appearance of a peak corresponding to 
reaction intermediates following the initial appearance of reaction products suggests the 
possibility of  multiple reaction pathways, one of which results in the slow accumulation of Pt(II)-
coordinated intermediates. The lower intensity of this peak at the 72 hr time point suggests that 
these intermediates are gradually converted to reaction products. The appearance of peaks 
corresponding to both 3’-5’ and 2’-5’ phosphodiesters leads us to conclude that the desulfurized 
products observed in MALDI-MS studies are in fact an approximately equal mixture of 3’-5’ and 
2’-5’ phosphodiester isomers.  
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Figure 5.3. Time course MALDI-MS spectra of Pt(II)-promoted cleavage, isomerization and 
desulfurization of PS-substituted RNA at pH 6.5. Product labels correspond to Figure 5.1. a) 
Enlargement of the spectral region between 1450 and 1600 amu. b) Full MALDI-MS spectra. c) 
Enlargment of the spectral region between 2950 and 3350 amu. Conditions identical to Figure 
5.1, times as noted in the figure. 
 
Accumulation of Platinum(II)-Coordinated Intermediates: 
     The observation of Pt(II)-coordinated intermediates (B) in both preliminary MALDI-MS 
studies and in NMR studies inspired us to further examine the build-up of these species 
throughout the course of platination of 5’-UUUUCpsCUUUU-3’ (A). As shown in Figure 5.3 
MALDI-MS was used to characterize the accumulation of Pt(II)-coordinated intermediates at 
times ranging from 3 min to 4 h. While MALDI-MS is not strictly quantitative, the intensities of 
two peaks within a narrow spectral window can be used to assess the relative abundance of each 
species in a given sample24 and here provide insight into the relative amounts of each product in 
the inset spectra. In these types of experiments, little to no Pt(II)-coordinated intermediates (B) 
are observed at early time points, while at 1 h these intermediates as well as reaction products (C, 
D, E) are clearly apparent. After 4 hours at pH 6.5, peaks corresponding to the parent PS-
substituted RNA are no longer observed and Pt(II)-coordinated intermediates are less abundant 
than at the 1 h time point, depicting conversion of both species to reaction products.  
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     An important question that arose during these studies concerned the identity of the Pt(II) 
species coordinated to the PS (see Scheme 5.1). The mass difference between the parent PS-
substituted RNA (A) (m/z= 3012) and peaks corresponding to the two Pt(II)-coordinated 
intermediates observed (e.g. Pt(NH3)-PS RNA (m/z = 3223) and Pt(NH3)2-PS RNA (m/z = 
3240)), do not depict other ligands expected to be present based on mono-functional coordination 
of a [Pt(NH3)2X] (X= OH2, OH, Cl) species to the PS. We have previously noted the absence of 
exchangeable Pt(II) ligands (e.g. OH, OH2, Cl) in MALDI-MS studies of Pt(II) coordination to 
RNA25 (and others to DNA26,27), however loss of an additional NH3 ligand was a new feature in 
these types of experiments. We hypothesized that loss of this ligand could result from the trans- 
labilizing effect of the PS sulfur atom.28 Strong experimental29 and theoretical30 evidence exists 
demonstrating loss of an Pt(II) NH3 ligand when trans to a thiol or thioether, suggesting that the 
NH3 ligand trans to the PS substitution may be similarly labilized.   
 
pH-Dependent Accumulation of Reaction Intermediates: 
     Initial MALDI-MS studies showed that this technique allowed detection of Pt(II)-coordinated 
RNA intermediates (B). Extending this, we hoped that by studying the accumulation of Pt(II)-
coordinated intermediates at various pH’s we would be able to comment on the relative stability 
of protonated versus deprotonated forms of these species. The pKa values of aqua ligands 
coordinated to [Pt(NH3)2XY]n+ (X,Y = OH2, -OH, Cl) species range from ~3.8 to 7.8 (depending 
on the identity of both exchangeable ligands).16,31 The pKa values of aqua ligands bound to a PS-
coordinated Pt(II) species are expected to lie within a somewhat similar range. The protonation 
state of both these species is expected to influence Pt(II)-phosphorothioate reactivity by 
determining the rate at which Pt(II) species coordinate to the anionic PS-substituted RNA as well 
as the rate at which they subsequently react (Scheme 5.1). We therefore conducted a series of 
MALDI-MS experiments, comparing the build-up of Pt(II)-coordinated intermediates at various 
pH’s after equivalent reaction times. As shown in Figure 5.4, at 4 h all PS-RNA reactants (A) 
have been consumed, except for in the reaction carried out at pH 8.0. Pt(II)-coordinated 
intermediates (B) are observed to accumulate to a large extent in reactions performed at pH 3.5. 
Surprisingly, this reaction also appears to predominantly form desulfurized products C and less 
cleaved products D and E. At pH 5.5 and pH 6.5 intermediate levels of Pt(II)-coordinated species 
(B) are observed along with significant amounts of cleaved and desulfurized products (C, D, and 
E) (Figure 5.4). The same intermediates are observed to a significantly lesser extent at pH 8.0 
and are accompanied by relatively low levels of reaction products.  
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Figure 5.4. The reaction of PS-substituted RNA with Pt(II) complexes after 4 h at different pH 
values. Product labels correspond to Figure 5.1. a) Enlargement of the spectral region between 
1450 and 1600 amu. b) Full MALDI-MS spectra. c) Enlargement of the spectral region between 
2900 and 3500 amu. Conditions as in Figure 5.1 with pH varied as indicated in the figure (see 
Materials and Methods, Appendix D). 
 
     The profiles of these pH-dependent reactions likely depict the influence of several competing 
equilibria in this reaction. First among these is the equilibrium occurring between protonated and 
unprotonated forms of [Pt(NH3)2XY]n+ (X,Y = OH2, -OH, Cl) compounds prior to reaction with 
the PS-substituted RNA (A). At low pH values this equilibrium is expected to favor cationic 
Pt(II) aqua species21 that are expected to associate faster with the anionic PS-substituted RNA 
than neutral Pt(II) hydroxo and chloride complexes present at higher pH.32-34 The presence of 
unreacted starting material (A) at 4 h at pH 8.0 fits well with this hypothesis.  Secondly, the 
accumulation of Pt(II)-coordinated RNA intermediates (B) at low pH (Figure 5.4c) suggests that 
these intermediates are stabilized by protonation. The observation that these Pt(II)-coordinated 
intermediates convert more to readily to products as pH increases from 3.5 to 6.5 further suggests 
that deprotonation of a PS-coordinated Pt(II) species may be important in determining the 
reaction’s progress. One model explaining these data is that at low pH values Pt(II)-aqua 
complexes rapidly coordinate to the PS-substituted RNA, but must be subsequently deprotonated 
in order to form cleaved and desulfurized products (Scheme 5.1).  This model supports the  
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Figure 5.5. Kinetic characterization of Pt(II)-induced cleavage of PS-substituted RNA. a) Kinetic 
traces obtained from experiments performed at indicated pH values depicting the reaction’s 
progress over 27 h. b) Kinetic data from time points ranging from 0 to 10 min. Data colored by 
pH: pH 8.0- blue, pH 6.5- black, pH 3.5- green. Data are the average of at least two experiments. 
Conditions as in Figure 1 with varying pH and buffer identity (see Material and Methods, 
Appendix D). 
 
proposition that a Pt(II)-bound hydroxo ligand acts as the general base in this reaction. 
Interestingly, this model can be extended to propose that Pt(II)-aqua species subsequently act as 
general acids (Scheme 5.1). Such a role for metal bound aqua ligands has been proposed 
previously for Zn2+ reactions.35 An alternative explanation of these data involves increasing 
cleavage activity by solvent-mediated deprotonation of the 2’-OH adjacent to the PS linkage at 
higher pH values. Although not completely discounted by the data in Figure 5.4, this possibility 
seems less likely based on the pH dependence observed in these experiments. Pt(II)-coordinated 
intermediates appear to efficiently react to form products at pH values of 5.5 and 6.5, well below 
the pKa  of ~15 expected for a solvent-exposed ribose 2’-OH.36  
 
pH-Dependent Kinetic Studies of Platinum(II) Promoted Cleavage: 
     Because MALDI-MS does not provide a strictly quantitative readout of reaction kinetics we 
simultaneously pursued kinetic studies using 5’ end-labeled RNA to monitor Pt(II)-induced 
cleavage  of 5’-UUUUCpsCUUUU-3’ at time points ranging from 30 sec to 27 h and at pH 
values of 3.5, 6.5, and 8.0. As shown in Figure 5.5, the rates of these reactions appear to increase 
with decreasing pH value, while total product yields show an inverse dependence on pH.  Thus, at 
~4 hrs the relative amounts of cleaved products are highest in the reaction carried out at pH 6.5, 
roughly matching the data obtained when the same reaction is analyzed by MALDI-MS (Figure 
5.4). Similarly, these data depict a fast but low-yielding reaction at pH 3.5 as well as a slower (but 
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eventually higher yielding) reaction at pH 8.0. The slower reaction rates observed at high pH 
suggest that Pt(II) coordination to the PS is rate-limiting under these conditions. This is expected, 
as coordination of the neutral [Pt(NH3)2ClOH] species present at pH 8.0 to an anionic PS-
substituted RNA should be slow relative to coordination of the cationic [Pt(NH3)2)Cl(OH2)]+ 
species present at pH 6.5 and below. The observation that reactions at pH 8.0 consistently 
produce more cleaved products than reactions performed at pH 6.5 or 3.5 correlates well with the 
hypothesis that once bound to the PS, Pt(II) hydroxo species are significantly more reactive. 
These observations remain qualitative, as preliminary attempts to fit kinetic data to single (or 
even second) order rate equations have not produced acceptable fits when both early and 
extended timepoints are considered simultaneously. This apparent complexity further suggests the 
importance of multiple equilbria in these reactions. One limitation of these experiments is that 
denaturing polyacrylamide gel electrophoresis (dPAGE) separation used to characterize these 
reactions is unable to provide the same resolution as MALDI-MS. Consequently, we are only able 
to measure the amount of RNA cleavage taking place in these experiments, but not the conversion 
of starting material to platinated intermediates (B) or desulfurized products (C). 
 
Activation of the Phosphorothioate Following Platinum(II) Coordination: 
     In addition to supplying a platform for general acid-base chemistry, Pt(II) coordination to a PS 
substitution is expected to withdraw electron density from the central P atom in the PS 
substitution, activating it towards nucleophilic attack. In order to provide a semi-quantitative 
analysis of this type of activation as well gain insight into the unique nature of a metal-
coordinated PS bond37,38 we carried out a series of preliminary computational studies aimed at 
determining the influence of the Pt(II) coordination on the buildup of positive charge at the P 
center. As a minimal model for a PS substitution we employed the molecule O,O’-
diethylthiophosphate. DFT calculations were carried out using a LAVCP extended B3LYP 6-
31G* basis set in order to accommodate the P, S and Pt atoms.39 The results of these experiments 
are shown in Figure 5.6. 
     These data depict several features relevant to discussion of Pt(II)-induced cleavage, 
desulfurization and isomerization of PS substitutions. First, based on its calculated atomic 
electrostatic charge, the thiophosphate P atom is predicted to be significantly less electropositive 
than an equivalent diethylphosphate analog. This feature is interesting when considered in the 
context in which PS substitutions are normally employed, where differences in metal ion affinity 
are typically considered to be the largest factor underlying the “thio effect”.10 Second, 
coordination of Pt(II) species to the PS is predicted to increase the electropositive nature of the P  
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Figure 5.6 Molecular modeling of Pt(II) coordination to O,O’-diethylthiophosphate. Structures, 
calculated electrostatic charge values, molecular structures and electrostatic potential maps 
computed using the BL3YP functional with a 6-31*G LAVCP-extended basis set. 
 
center, restoring it to roughly the same level of electrostatic charge predicted for the 
diethylphosphate analog. Third, the structures predicted for these complexes depict the potential 
for hydrogen bonds to form between Pt(II) ligands and esteric oxygens (Scheme 5.1b). This 
feature suggests that a Pt(II)-aqua species could be placed within proper proximity to act as a 
general acid in the pathways proposed in Scheme 5.1. This finding further suggests that 
exchange-inert Pt(II) ligands may not be “innocent bystanders” in these reactions.40 Aqua and 
hydroxo ligands in particular may form hydrogen bonds which could stabilize conformations of 
PS-coordinated Pt(II)-species and potentially influence pseudorotation (Scheme 5.1b). Finally, 
the identity of the “X” ligand in these complexes seems to have a minimal effect on activation of 
the P center. This finding contrasts an alternative hypothesis in which the electron withdrawing 
capacity of these ligands could be expected to influence PS reactivity.  
 
Proposed Mechanism Describing Platinum(II) Phosphorothioate Reactivity: 
     Cumulatively, current data suggest the mechanism proposed in Scheme 5.1 for reactions of 
Pt(II) species with PS-substituted RNA oligonucleotides. In this mechanism a cationic 
[Pt(NH3)2(OH2)X]+ (X = OH2, Cl-, -OH) complex coordinates to a PS thio ligand. A Pt(II)-
coordinated hydroxo ligand is then responsible for deprotonating the adjacent 2’-OH. This 
hypothesis is supported by the accumulation of Pt(II)-coordinated intermediates at low pH. 
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Following deprotonation, an anionic phosphorane intermediate is formed, stabilized by Pt(II) 
coordination to the S atom. Pseudorotation around this intermediate can place either the 3’ 
nucleotide or the Pt(II)-coordinated S atom in an apical position, poised to depart. The anionic 
oxygen of the thiophosphorane is not expected to be apically positioned based on previous work 
showing a lack of isomerization and desulfurization observed in hydroxide-catalyzed cleavage of 
PS substitutions.12 Departure of either axial substituent may be facilitated by a metal-bound aqua 
ligand acting as a general acid by protonating the leaving group.35 This would be an interesting 
example of how a single metal ion could provide both general acid and general base roles in 
phosphoryl transfer catalysis. Departure of the 3’ nucleotide from the thiophosphorane 
intermediate results in Pt(II)-coordinated cyclic thiophosphates which seem to undergo rapid 
hydrolysis based on our inability to detect these species in our experiments. Interestingly, a Pt(II) 
aqua ligand could be envisioned to facilitate the hydrolysis of these complexes as well by 
potentially donating a proton to the departing thiol (Scheme 5.1). In the alternative 
thiophosphorane conformation, an axial Pt(II) thiol species departs. This would result in a 
sterically encumbered and unstable phosphotriester expected to undergo rapid hydrolysis to a 
mixture of 3’-5’ and 2’-5’ phosphodiester isomers as well as cleaved RNA products. Pt(II) thiol 
species result in all of these potential mechanisms. Interestingly we detect a number of low-
nuclearity Pt(II) clusters of the general form [Pt(NH3)S]nNa by MALDI-MS following these 
reactions (Figure D.1). The mechanism described here fits well with the experimental evidence 
gathered to date, although several important aspects of this reaction remain to be explored. 
Primary among these are determining the pKa of the aqua ligand bound to Pt(II) while it is 
coordinated to the PS, and direct measurements of Pt(II)-PS association rates.  
     Phosphoryl transfer reactions are critical in biology.41,42 Metal ions often play essential roles in 
these types of reactions, especially in RNA.4-7,43  Our understanding of these roles has been 
greatly extended by the use of site-specific PS substitutions.7-9 Building on this, coordination of a 
Pt(II) species to the sulfur atom of a PS has been shown to be capable of activating site-specific 
RNA cleavage, desulfurization, and isomerization. The reaction leading to these products is 
proposed to occur through the mechanism described in Scheme 5.1. Developing a thorough 
understanding of the equilibria in this system may lead to the development of new experimental 
models for phosphoryl transfer catalysis44,45 as well as provide insight into the myriad of ways in 
which Nature uses metal ions to perform similar chemistry in the core of complex cellular 
machines.  
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Future Work- Determining the pKa of Aqua Ligand Bound to a Platinated 
Phosphorothioate: 
     The O,O’-diethylthiophosphate molecule employed in DFT studies may provide a useful 
experimental model for determining the pKa an of aqua ligand bound to a PS-coordinated Pt(II) 
center. Spectroscopic handles exist in this system include 1H and 31P NMR features. UV-active 
charge-transfer bands are also expected between Pt(II) and S and may also provide information 
regarding the protonation state of a Pt(II) coordinated aqua/hydroxo ligand. Monitoring changes 
in these spectral features as a function of pH should provide the means to ascertain the acidity of 
the aqua ligand bound to Pt(II). 
  
Future Work- Synthesis of Platinum Triammine Complexes: 
     An interesting and important control to many of the preceding experiments will involve 
synthesis of [Pt(NH3)3Cl]+.47 A third exchange-inert NH3 ligand is expected to preclude formation 
of reactive, PS-coordinated Pt(II) aqua species (Scheme 5.1) and shut down pathways that 
depend on intramolecular proton transfer. It also seems possible, given the absence of a second 
coordinated NH3 in preliminary MALDI-MS studies (see previous sections), that the NH3 ligand 
trans to the PS S atom may be labilized. Synthesis of Pt(II) complexes with chelating triamine 
ligands will presumably prevent loss of this ligand and allow us to fully explore this mechanism. 
 
Summary and Bridge to Chapter VI: 
   Chapter V describes the reaction of Pt(II) complexes with phosphorothioate-substituted RNAs. 
Surprisingly, in addition to cleaved RNA products, this reaction produces a mixture of 3’-5’ and 
2’-5’ phosphodiesters in place of the original phosphorothioate substitution. As outlined in 
Scheme 5.1, this reaction is believed to proceed through a stabilized pentacoordinate 
phosphorane intermediate. Continued studies aimed at determining the role of Pt(II)-coordinated 
ligands in the proposed mechanism may help further define the chemical basis for the “thio 
effect”. Chapter VI again touches on these studies as it summarizes the insights gained regarding 
Pt(II) coordination to RNA and the future of this type of research. 
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CHAPTER VI 
 
CONCLUDING REMARKS AND FUTURE DIRECIONS 
 
Introduction: 
     This chapter includes topics generated by the mixing of ideas in the collaborative research 
environment fostered in the DeRose lab. Dr. Vickie DeRose is wonderfully curious and many of 
the ideas discussed in this chapter are her original ideas. Individuals in our lab have already 
begun work on several of these projects. Specifically, ongoing studies trying to understand the 
effects of Pt(II) drug treatment on RNA biology in yeast are actively being pursued by both 
Alethia Hostetter and Maire Osborn. Many of the ideas discussed in the ‘technological 
applications’ section of this chapter are independent ideas I have entertained during the last year 
during my search for a new place to pursue scientific research.  
 
Concluding Remarks: 
This dissertation describes how Pt(II) complexes coordinate to RNA. Chapter I outlines how 
the coordination chemistry of relatively simple square-planar Pt(II) compounds enables their use 
as frontline antitumor drugs. While for many years DNA has been the accepted molecular target 
of Pt(II) antitumor complexes, a small but growing line of evidence points towards the possibility 
that RNA targeting may also contribute to the in vivo activity of these drugs. Chapter II describes 
the ability of Pt(II) complexes to rapidly form intramolecular crosslinks in a structured RNA. 
RNA’s ability to fold into incredibly complex biomolecular architectures, harboring features such 
as pre-formed metal ion coordination sites, raises important questions regarding how Pt(II) 
complexes may bind to these diverse and intricate structures. Chapter III describes how Pt(II) 
coordination to RNA influences the activities of RNA processing enzymes similar to those used 
by the cell to tailor RNA so that it may act in a myriad of biological roles. Pt(II) coordination 
generally disrupts the function of these enzymes raising new questions regarding how RNA 
damage inflicted by Pt(II) coordination is manifested in the mechanisms of Pt(II) antitumor drugs. 
This chapter also describes the reversal of Pt(II)-RNA adducts by thiourea, demonstrating the 
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relative affinity of Pt(II) for sulfur. In Chapter IV this thiophilicity is capitalized upon in the 
engineering of a new RNA-RNA crosslinking strategy based on the selective targeting of Pt(II) 
complexes to phosphorothioate substitutions installed at specific locations within RNAs. A 
phosphorothioate substitution installed in the catalytic core of the Hammerhead ribozyme recruits 
Pt(II) complexes to this site, anchoring them to this position where they can subsequently form 
crosslinks to nearby nucleotides in the active site of this catalytic RNA. Similarly, Pt(II) 
coordination to phosphorothioate substitutions embedded between ribonucleotides is able to 
activate a series of phosphoryl transfer reactions that result in both RNA cleavage as well as the 
isomerization of the phosphorothioate bond to produce a mixture of 3’-5’ and 2’-5’ 
phosphodiesters. Chapter V describes this reactivity, which seems to be based on the unique 
stabilization of a phosphorane intermediate. Cumulatively, these studies survey many aspects of 
Pt(II)-RNA chemistry and lay the groundwork for continued research aimed at determining the 
consequences of platinating cellular RNAs as well the creation of new nucleic acids technologies 
based on Pt(II) coordination to RNA. 
  
Elucidating the Effects of Platinum(II) Coordination to RNA In Vivo: 
     Because Pt(II) antitumor drugs coordinate to many targets including proteins, DNA and RNA, 
elucidating the specific effects of Pt(II) coordination to RNA in vivo is a daunting task. Figure 
6.1 outlines a variety of important questions regarding the in vivo targeting of RNA and several 
experimental strategies that may be used to address them. These questions range from 
determining binding locations of Pt(II) antitumor drugs in specific RNA targets, to understanding 
broader effects such as the influence of Pt(II)-RNA damage in inducing apoptosis.  
     Specifically, the ability of Pt(II)-RNA adducts to disrupt reverse transcription (as described in 
Chapter III), has enabled us to begin to ask questions regarding specific Pt(II) binding locations in 
vivo. Ongoing research has employed primer extension analysis to characterize Pt(II) drug 
binding to ribosomes in S. cereviseae. Already these studies are producing exciting results, 
showing platination of both solvent-exposed nucleotides and nucleotides located in more buried 
regions including the peptidyl transferase center (Osborn and DeRose, unpublished).  
     Another line of research has begun to ask how translation is affected by Pt(II) coordination to 
mRNA targets. In these studies, RNA sequences expected to be targeted by Pt(II) antitumor drugs 
have been embedded within the untranslated regions of mRNAs encoded for on plasmid vectors.  
When such a structure is placed between regions of an mRNA that encode specific fluorescent  
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Figure 6.1. Ongoing research questions regarding the effects of platinating RNA in the cell. 
 
reporters, we hope to monitor differential expression levels as a means of assessing the effects of 
Pt(II) antitumor drug binding to mRNA on translation.  
     The use of thiourea to reverse Pt(II)-RNA adducts (as described in Chapter III), is one 
component of developing a means to survey the different types RNAs targeted by Pt(II) drugs 
using “pull-down” type experiments.  In such a strategy Pt(II) ligands could be engineered to 
allow selective recovery of Pt(II)-bound RNAs. Reversal of Pt(II)-RNA adducts, potentially using 
thiourea, followed by amplification of these sequences would allow us to address the sequence 
contexts and perhaps structural motifs targeted by Pt(II) complexes.  
     Next, the selective isolation of different types of RNA from Pt(II)-treated cells may provide 
new insights into how factors such as cellular localization affect the types of RNAs targeted by 
Pt(II) antitumor drugs. Alethia Hostetter is currently using inductively coupled plasma mass 
spectrometry (ICP-MS) to quantify Pt(II) drug binding in these types of experiments. Preliminary 
results show substantial platination of both mRNA and rRNA (Hostetter and DeRose, 
unpublished). 
     Finally, in studies also being pursued by Alethia Hostetter, we have become interested in the 
ability of cisplatin to initiate apoptosis in yeast. Using selective staining techniques in 
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combination with high resolution fluorescence microscopy, we are gaining new insights into the 
in vivo biological effects of Pt(II) antitumor drugs. 
     Combined, the aforementioned studies are an essential component of forming a 
comprehensive description of the molecular mechanisms of Pt(II) antitumor drugs. 
 
Technological Applications of Platinum(II) Coordination to RNA: 
      In unmodified RNA and DNA sequences, Pt(II) typically coordinates to the N7 atom of both 
G and A nucleotides. Because these nucleotides comprise approximately half of the genome, 
technological applications of Pt(II) coordination must either capitalize on this broad specificity or 
artificially enhance it to achieve homogenous populations of platinated oligonucleotides. Both of 
these strategies are being pursued in the development of a number of new technologies including 
our own efforts to engineer new RNA crosslinking strategies. 
     In one high profile example of coordinating Pt(II) to both DNAs and RNAs, the biotechnology 
start-up firm Halcyon Molecular has promised to deliver a “$100 genome” based on the selective 
labeling of nucleic acid sequences using Pt(II).1 Using recently developed methods to stretch 
single strands of genomic DNA over silicon slides2 the company aims to selectively label G and T 
nucleotides using Pt(II) and Hg(II) respectively. Using dark field scanning transmission electron 
microscopy3 to detect base-specific heavy-atom labeling, the company has promised to provide 
accurate, full-length reads in under 10 minutes and transform biomedicine into an ‘information 
science’. Extending this technology to RNA may involve significant hurdles, however these 
efforts emphasize the utility of Pt(II) in nucleic acids technologies. 
     One of the major outstanding challenges in RNA science lies in determining the structures of 
the RNAs that comprise the transcriptome. While X-ray crystallography has proven to be an 
invaluable tool, this technique is limited in its ability to keep pace with an ever-expanding list of 
important biological RNAs. Along these lines, several research groups are developing strategies 
to map RNA structure in solution using chemistries amenable to high-throughput analysis. The 
“MOHCA bombs” developed by Das and coworkers4 as well as SHAPE chemistry pioneered by 
the Weeks group5 lead these efforts. Similarly, we hope to adapt the crosslinking strategy 
described in Chapter IV to function in higher throughput contexts. The ability to statistically 
incorporate phosphorothioate substitutions into RNA sequences by transcription using α-thio-
NTP’s6 would provide a starting point for this development. Following crosslinking of these 
RNAs by Pt(II) complexes a combination of strategies including exonuclease digestion, Pt(II) 
removal by thiourea, and/or cleavage of embedded phosphorothioate substitutions by iodine 
reagents7 could provide the means to identify crosslinked positions. Overlaying these results on 
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the predicted secondary structure of a given RNA could provide important information regarding 
the folded structure of the RNA in solution and add to the expanding list of techniques being used 
to rapidly probe RNA structure. 
     Finally, although not a strict ‘technological’ application, the opportunity to use the reactivity 
observed between Pt(II) complexes and phosphorothioate substitutions described in Chapter V 
may hold potential to provide a new model system for studying phosphoryl transfer reactions both 
in structurally simple situations and in the complex active sites of ribozymes. The ability of Pt(II) 
coordination to act as a platform for general acid-base chemistry may help reveal the role metal 
ions play in facilitating catalysis in these systems.  
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APPENDIX A 
 
SUPPORTING INFORMATION FOR CHAPTER II: RAPID CROSSLINKING OF AN 
RNA INTERNAL LOOP BY THE ANTICANCER DRUG CISPLATIN 
 
 
Materials and Methods: 
Nucleic Acid Substrates: All RNAs, except BBD, were purchased from Dharmacon, Inc. DNA 
was purchased from Integrated DNA Technologies. BBD was transcribed in vitro from a plasmid 
template using T7 RNA polymerase. All nucleic acid substrates were purified by 20% dPAGE, 
eluted, then desalted and concentrated using Millipore YM-3 Centricon tubes. Subsequent buffer 
exchange and desalting was often accomplished using GE Healthcare G-25 microspin columns. 
5′ End-Labeling: Prior to radiolabeling, the 5′ end of BBD was dephosphorylated using 
Antarctic phosphatase (New England Biolabs). 5′-OH Oligonucleotides were end-labeled with T4 
poly-nucleotide kinase (USB) using γ32P-ATP (Perkin-Elmer). End-labeled oligonucleotides 
were purified by 20% dPAGE followed by overnight elution from excised gel bands. The 
resulting eluent was ethanol-precipitated and desalted or buffer-exchanged as described above. 
Cisplatin Aquation: Cisplatin (Sigma-Aldrich) was stored as a 1 mM solution in 10 mM NaCl in 
the dark at 4 °C. Immediately before use, cisplatin was aquated with 0.95 equiv of 12 mM 
AgNO3 (stored in the dark). The aquation reaction was incubated at 50 °C for 1 h, at which time 
AgCl was precipitated by centrifugation. The supernatant solution was removed and diluted 
accordingly. On the basis of 195Pt NMR (data not shown), the main platinum species varied by 
pH: [Pt(NH3)2Cl(OH2)]+ for pH 6.8 and [Pt(NH3)ClOH] for pH 7.8. 
Platination of BBD (Figure 2.2b): A trace amount of 5′ end-labeled BBD with 0.2 µM 
unlabeled BBD was annealed by heating to 90 °C for 90 s followed by cooling to room 
temperature, then reacted with 0–40 µM cisplatin in deionized water for 1.5 h at 37 °C. The bulk 
reaction mixtures were mixed with formamide loading buffer and immediately applied to 18% 
dPAGE. Results were imaged using a Molecular Dynamics phosphor screen and scanned on a 
Molecular Dynamics Storm 860. 
Comparative Platination of SBBD and BBD (Figure 2.2c): Twenty micromolar (0.2 nmol) of 
BBD RNA, each individual SBBD strand, or the SBBD hybrid was annealed and rested on ice for 
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30 min. RNAs were then incubated in the presence of absence of 200 µM cisplatin (added as a 1 
mM solution with 8 mM NaCl) in 5 mm triethanolamine (TEA) pH 6.8 for 12–16 h at 37 °C. 
Reaction mixtures were analyzed on 20% dPAGE and visualized by staining with methylene 
blue. 
Isolation of 5′ End-Labeled, Cross-Linked RNAs: BBD: 5′ End-labeled BBD in the presence 
of 0.1 µM unlabeled BBD was annealed and reacted with aquated cisplatin in 100 mM NaNO3, 1 
mM Mg(NO3)2, and 5 mM 3-(N-morpholino)propanesulfonic acid (MOPS) (pH 6.8) at 37 °C for 
23 h. Reaction products were isolated via excision from 18% dPAGE. RNA was eluted overnight 
into deionized water and desalted using in-house prepared G-25 sephadex spin columns 
(BioRad). SBBD: One 5′ end-labeled strand was annealed in 10 µM of the unlabeled complement 
RNA in 12.5 mM NH4NO3 and reacted with 100 µM aquated cisplatin for 23 h. The cross-linked 
product was excised from 20% PAGE and eluted overnight into deionized water. Following 
speedvac concentration, SBBD cross-links were desalted using G-25 sephadex spin columns (GE 
Healthcare). 
Hydrolysis Mapping of Cross-Linked RNAs: Trace 5′ end-labeled, cross-linked RNAs were 
dried to completion in the presence of 0.2 pmol unlabeled RNA corresponding to the 5′ end-
labeled strand. Samples were then resuspended in 50 mM Na2CO3/NaHCO3 (pH 9.5) and 1 mM 
EDTA and reacted at 90 °C for times ranging from 5 to 25 min. The reaction was quenched by 
the addition of 8 M urea, 10 mM sodium citrate (pH 3.5), and 0.005% (w/v) xylene cyanol 
loading buffer and held on dry ice until electrophoresis. The results were analyzed on 15 or 20% 
dPAGE (BBD and SBBD, respectively) then visualized via phosphorimaging. 
      Reference lanes of 5′ end-labeled un-cross-linked RNAs were generated from hydrolysis as 
above and by partial nuclease digestion by RNase T1 (Ambion) or U2 (Pierce/Thermo Scientific). 
Briefly, 5′ end-labeled RNA with 0.2 µM of the corresponding unlabeled RNA in 8 M urea, 10 
mM sodium citrate (pH 3.5), and 0.005% (w/v) xylene cyanol was reacted for at 50 °C for 12–15 
min with 1U T1 RNase or 0.2U U2 RNase. Samples were then held on dry ice until 
electrophoresis. 
Kinetic Analysis: Prior to kinetic analysis, 0.1 µM oligonucleotide with trace 5′ end-labeled 
material was annealed in buffered solution by heating to 90 °C for 90 s followed by gradual 
cooling to room temperature or, for the case of the SBBD hybrid, resting on ice for 30 min. 
Buffers included either 100 mM NaNO3, 1 mM Mg(NO3)2, and 5 mM triethanolamine (TEA) (pH 
7.8) or 100 mM NaNO3, 1 mM Mg(NO3)2, and 5 mM (MOPS) (pH 6.8) depending on desired pH. 
Freshly aquated cisplatin was added to final concentrations of 13, 25, or 50 µM, and the reactions 
were incubated at 37 °C for times ranging from 1 min to 35 h. Aliquots were removed and 
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stopped by ethanol precipitation or dilution with formamide and freezing. These aliquots were 
applied to 18–19% dPAGE and visualized by autoradiography. Each kinetic experiment was 
repeated at least three times. Molecular dynamics ImageQuant software version 5.0 was used to 
quantify the reaction mixtures from each kinetics experiment. Rate constants were generated from 
data analysis using SigmaPlot version 8.0. 
MALDI-MS: Isolation of platinated oligonucleotides for MALDI-MS analysis: 30 µM of an 
oligonucleotide was annealed in 100 mM NaNO3, 1 mM Mg(NO3)2, and 5 mM MOPS (pH 6.8) 
and reacted with either 90 µM aquated cisplatin for LSBBD or 150 µM for RNA HP and DNA 
HP. Samples were incubated at 37 °C for 5 h, at which time they were applied to 19% dPAGE. 
Products were stained with methylene blue and excised. Oligonucleotides were recovered via 
electroelution using a Schleicher and Schuell Elutrap electro-separation system, concentrated, and 
desalted. Bulk time-course reactions for MALDI-MS analysis: 0.6 nmol of an oligonucleotide 
was reacted under identical conditions to those used in kinetics experiments (see above). 
Reactions were incubated for 1 or 23 h and stopped by ethanol precipitation, dried, and desalted 
using G-25 sephadex spin columns. 
      Oligonucleotide samples (~50–100 pmol) were additionally desalted on C18 ZipTips 
(Millipore) following the manufacturer’s protocol for RNA. RNA was eluted in a matrix solution 
containing 41 mg/mL 3-hydroxypiccolinic acid and 4.5 mg/mL diammonium citrate then applied 
to the sample plate. MALDI-MS analysis was performed on a Waters QTof Premier mass 
spectrometer in positive-ion mode using V-mode optics. 
SBBD Thermal Denaturation: Thermal denaturation of SBBD, in a “kinetics” buffer of 100 
mM NaNO3, 1 mM Mg(NO3)2, and 5 mM TEA (pH 7.8), was monitored on a Varian Cary 300 
Bio UV–visible spectrophotometer with multicell holder and temperature controller. These data 
were fit with the accompanying software, giving a Tm of 59 °C and a calculated Kd at 37 °C of 
6.8 × 10−9 M. On the basis of this Kd, approximately 60% of the SBBD hybrid would be formed 
during the kinetic analyses, which used a concentration of 0.1 µM for each SBBD strand. 
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 Figure A.1: 
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Figure A.1. Location of platinum crosslinks formed with SBBD1. (a) The predicted secondary 
structure of hybridized SBBD1 and SBBD2 RNAs with the location of the major cisplatin 
induced crosslink on the SBBD1 strand highlighted. (b) 20% dPAGE analysis of the products of 
partial alkali hydrolysis of the SBBD crosslink with 5’-end-labeled SBBD1. Lanes: Control- C: 
5’ end-labeled SBBD1. T1: G specific sequence ladder generated by partial nuclease digestion of 
SBBD1 RNA by T1 RNase. U2: A specific sequence ladder generated by partial nuclease 
digestion of SBBD1 RNA by U2 RNAse. OH-: Reference alkali hydrolysis ladder for SBBD1. 
SBBD Crosslink Samples- C: dPAGE-isolated SBBD crosslink. OH- Lanes: dPAGE-isolated 
SBBD crosslink treated under alkali hydrolysis for increasing amounts of time. 
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Figure A.2: 
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Figure A.2. Location of platinum crosslinks formed with SBBD2. (a) 20% denaturing PAGE 
analysis of the products of partial alkali hydrolysis of the SBBD crosslink with 5’-end-labeled 
SBBD2. Lanes: Control- C: 5’ end-labeled SBBD2. T1: G-specific sequence ladder generated by 
partial nuclease digestion of SBBD2 RNA by T1 RNase. U2: A-specific sequence ladder 
generated by partial nuclease digestion of SBBD2 RNA by U2 RNAse. OH-: reference alkali 
hydrolysis ladder for SBBD2. SBBD Crosslink Samples- C: dPAGE-isolated SBBD2 crosslink 
OH- Lanes: dPAGE-isolated SBBD crosslink treated under alkali hydrolysis for increasing 
amounts of time. (b) The predicted secondary structure of hybridized SBBD1 and SBBD2 RNAs 
with the location of the major [Pt(NH3)2]2+ on the SBBD2 strand highlighted. 
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Figure A.3: 
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Figure A.3. Kinetic analysis of SBBD crosslinking. (a) dPAGE radiograms depicting products of 
cisplatin binding to SBBD in pH 6.8 and 7.8 over time. (b) Comparison of the reaction rates of 
SBBD in pH 6.8 (filled circles) and 7.8 (open circles). Conditions: (a) Reactions were performed 
with 0.1 µM SBBD duplex with either 50 µM cisplatin in 5 mM TEA (pH 7.8) or 25 µM cisplatin 
in 5 mM MOPS (pH 6.8). Both reactions were in 100 mM NaNO3, 1 mM Mg(NO3)2, and at 37 
°C. Reactions analyzed by 20% dPAGE. 
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Figure A.4: 
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Figure A.4.  Platinum(II) concentration-dependent crosslinking of BBD RNA. (a) BBD kinetics 
with 50 μM (filled circles), 25 μM (open circles), and 12.5 μM (triangles) cisplatin. (b) Observed 
rate constant (kobs) versus cisplatin concentration. Conditions: Reactions were performed in 100 
mM NaNO3, 1 mM Mg(NO3)2, and 5 mM TEA (pH 7.8) at 37 °C. 
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Table A.1: 
Constructa  µM CP pH kobs (10-4 min-1) krxn2 (M-1 s-1)b 
BBD 50 7.8 59(6) 2.0(2) 
BBD 25 7.8 30(2) 2.0(1) 
BBD 12.5 7.8 17(2) 2.3(2) 
BBD 25 6.8 128(11) 8.5(7) 
RNA HP 50 7.8 50(1) 1.7(3) 
DNA HP 50 7.8 10(1) 0.33(3) 
SSBBD 50 7.8 31(2) 1.1(1) 
SSBBD 25 6.8 102(3) 6.8(2)  
Table A.1. Platination rates of RNA and DNA constructs. a) All experiments used 0.1 µM 
oligonucleotide (or 0.1 mM SBBD duplex) and were performed at 37 °C with 100 mM NaNO3 
and 1 mM Mg(NO3)2. Trials at pH 7.8, and 6.8 were done in 5 mM TEA and MOPS respectively. 
b) Because all kinetics were performed under pseudo-first order conditions, second order rate 
constants were obtained by dividing kobs by the concentration of cisplatin used.  
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APPENDIX B 
 
SUPPORTING INFORMATION FOR CHAPTER III: ENZYMATIC PROCESSING OF 
PLATINATED RNAS  
 
 
Materials and Methods: 
Nucleic Acid Substrates: 13-mer RNAs were ordered from Dharmacon, Inc., deprotected 
following the manufacturer’s protocol and were reacted without further purification. DNA was 
purchased from Integrated DNA Technologies. PEBBD was transcribed from a dsDNA template 
containing primers necessary for PCR amplification and for transcription by T7 RNA 
polymerase. Following transcription PEBBD RNA was purified using 15-20% dPAGE, eluted 
then desalted and concentrated using Millipore YM-3 Centricon tubes. Subsequent buffer 
exchange and desalting was often accomplished with G-25 Sephadex size exclusion resin (GE 
Healthcare) on laboratory prepared microcentrifuge columns (BioRad). Oligonucleotide 
concentrations were determined using a Varian Cary 300 Bio UV-visible spectrophotometer. 
Cisplatin Aquation: Cisplatin (Sigma-Aldrich) was stored as a 1mM solution in 10mM NaCl 
and stored in the dark at 4 °C. Immediately before use, cisplatin was aquated by reaction with 
0.95 equiv. of 12mM AgNO3 (stored in the dark). The aquation reaction was incubated at 50°C 
for 1 h, at which time AgCl was precipitated by centrifugation. The supernatant solution was 
removed and diluted accordingly. The predominant platinum species formed varies by pH with 
[Pt(NH3)2Cl(OH2)]+ expected to be the main Pt-complex present at pH 7.0 (by 195Pt NMR, data 
not shown).    
Platination of 13-mer RNAs: 80µM RNA (typically 8 nmol) was reacted with 240 µM aquated 
cisplatin in the presence of 1mM Mg(NO3)2, 100 mM NaNO3, in 10 mM Na2PO4 buffer (pH 7.0) 
for 16 hr, 37 °C. Reactions were stopped by application to G-25 Sephadex spin-columns to 
remove unbound platinum, then eluted and dried to completion by SpeedVac, and resuspended in 
deionized water. At this time aliquots were removed and subjected to MALDI-MS in order to 
establish proper platination. MALDI-MS showed these reaction conditions to produce 
predominantly mono-platinated RNAs that were then used in nuclease-processing studies without 
further purification.  
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     No significant amount of intermolecular crosslinked products were observed, even between 
platinated 5’-(U)6-GU-(U)5-3’ RNA strands, and attempts to force such crosslinking were 
unsuccessful (data not shown). Presumably, even under the moderately strong ionic conditions 
employed (120 mM Na+, 1mM Mg2+) electrostatic repulsion between two negatively charged and 
non-complementary RNA oligonucleotides prevents platinum crosslinking. 
3’à5’ Venom Phosphodiesterase (VPD) Digestion of Platinated RNAs: Venom 
phosphodiesterase from Crotalus adamanteus (Phosphodiesterase I, VPD) was obtained as a 
lyophilized solid (Sigma-Aldrich).  ~5 mg of the white solid (≥0.01 unit/mg) was dissolved in 
500 uL of a 50% glycerol solution containing 10 mM Zn(OAc)2 and used as an enzyme stock  of 
~1 x 10-4 U/ul. Digestion reactions were carried out by addition of ~1 x 10-4 U of VPD stock to 
400 pmol of platinated RNA (100 µM in H2O).  Reactions were incubated 2 h at 50 °C at which 
time protein was removed by phenol-chloroform extraction and two washes with 24:1 
chloroform:isoamylalcohol.  The aqueous layer was retained and dried to completion by 
SpeedVac. RNA was further purified by C18 ZipTips (Millipore) before MALDI-MS (vida infra). 
5’à3’ Spleen Phosphodiesterase (SPD) Digestion of Platinated RNAs: Calf spleen 
phosphodiesterase (Phosphodiesterase II, SPD) was obtained as a 0.1 U/uL 50% glycerol solution 
(EMD Chemicals) and used as received.  Digestion reactions were carried out by addition of 0.1U 
SPD to 400pmol of platinated RNA (~100 µM in H2O).  Reactions were incubated 4hr at 50 °C at 
which time protein was removed by phenol-chloroform extraction and two washes with 24:1 
chloroform:isoamylalcohol.  The aqueous layer was retained and dried to completion by 
SpeedVac. RNA was further purified by C18 ZipTips before MALDI-MS (vida infra). 
RNase U2 Digestion of Platinated RNAs: RNase U2 was obtained as a 1 U/uL, 50% glycerol 
solution (ThermoScientific) and used as received.  Digestion reactions were carried out by 
addition of 1U RNase U2 to 400 pmol platinated or un-platinated RNA (~100 µM in H2O).  
Reactions were incubated 1 h at 50 °C and were then purified by C18 ZipTips prior to MALDI-
MS analysis (vida infra). 
MALDI-MS: Dried RNA samples were resuspended in deionized water and purified using C18 
ZipTips using a procedure modified from the manufacturer’s protocol for RNA58: ZipTips were 
washed by aspiration three times with 1:1 MeCN:H2O, and equilibrated by washing three times 
with 0.1% trifluoroacetic acid (TFA). RNAs were bound to the tip by repeated aspiration of the 
analyte solution. Bound RNA was washed three times by aspiration with 0.1% TFA, three times 
with deionized water, and then eluted from the column using two washes of 1:1 MeCN:H2O.  The 
eluent was dried to completion by SpeedVac and resuspended in a matrix consisting of 375 mM 
2’,4’,6’-trihydroxyacetophenone (THAP, Sigma-Aldrich), 30 mM diammonium citrate in 3:1 
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EtOH:H2O, with added NH4+ loaded Dowex cation exchange beads (Aldrich) and applied to the 
sample plate.  MALDI-MS analysis was performed on a Waters QToF Premier mass spectrometer 
in positive-ion mode using V-mode optics. 
5’ End-Labeling:  The DNA primer used for reverse transcription of PEBBD was radiolabeled 
with T4 poly-nucleotide kinase (Fermentas) using γ32P-ATP (Perkin-Elmer).  The end-labeled 
primer was purified by 20% dPAGE, imaged by phosphor screen and excised. Excised gel bands 
were eluted overnight in deionized water.  The resultant eluent was ethanol precipitated and 
further desalted using G-25 Sephadex spin-columns.   
Platination of PEBBD: 20 µM (200 pmol) PEBBD RNA was annealed and platinated with 0 to 
1 equiv activated cisplatin in 1 mM Mg(NO3)2, 10 mM NaNO3, 5 mM 3-
morpholinopropanesulfonic acid (MOPS), pH 6.8 for 12 h at 37 °C. Reactions were passed 
through G-25 Sephadex spin-columns to remove unbound platinum, and the eluent was dried to 
completion by SpeedVac.  Reactions were resuspended in deionized water prior to reverse 
transcription. 
Reverse Transcription of Platinated PEBBD: Platinated PEBBD samples were reverse 
transcribed using M-MuLV reverse transcriptase (Fermentas) using a procedure based on the 
manufacturer’s protocol.  Briefly, 100pmol of the appropriate 5’-end-labeled DNA primer was 
annealed to platinated PEBBD in the manufacturer’s supplied reaction buffer and then incubated 
at 42 °C for 1 h after addition of the enzyme. The reactions were diluted with formamide loading 
buffer containing 0.005% (w/v) xylene cyanol and bromophenol blue and analyzed using 15% 
dPAGE. ImageQuant version 5.0 software(Molecular Dynamics) was used to quantify band 
intensities.  Microsoft Excel 2004 was used to normalize and graph Image Quant generated 
intensity values.  
Sequence referencing lanes were generated with a Sequenase Version 2.0 DNA Sequencing kit 
(USB Corporation) following the manufacturer’s protocol, using an appropriate DNA template 
and the same 5’ end-labeled primer used with PEBBD. 
Platinum Removal by Thiourea: 400 pmol of the platinated 5’-(U)6-GU-(U)5-3’ or 5’-(U)6-GG-
(U)5-3’ RNA (200 µM in H2O, 2 uL) was reacted with an equal volume (2 uL) of a saturated 
thiourea solution.  Reactions were incubated at 37 °C for varying amounts of time, purified using 
C18 ZipTips and analyzed by MALDI-MS. 
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PEBBD RNA Sequence and Primers: 
PEBBD:  
5’- GGAAGACAAGAAUAACGCUCAAGCAUCAAGUGUAGUAUCCGAAAGGAUACAG 
AGAAGAUGCUUCGACACGAUGCUCACAACAGAC -3’ 
 
RT PRIMER:  
5’- GTCTGTTGTGAGCATCGTGTCGAA-3’ 
 
Standard Transcription Conditions: 
An DNA template encoding a consensus T7 promoter sequence immediately before the PEBBD 
sequence as well primers appropriate for PCR amplification were obtained from Integrated DNA 
Technologies. Following amplification and Taq fill-in, DNA templates were annealed and 
transcribed using T7 RNA polymerase expressed in our laboratory. A typical transcription 
reaction contained ~1ug/uL DNA template, 0.01U/uL inorganic pyrophosphotase,  ~0.1 ug/uL T7 
RNA polymerase and 100 mM NTP’s in a solution of 12 mM MgCl2, 2 mM spermidine, 40 mM 
dithiothreitol, 80 mM HEPES, pH 7.5. Transcription reactions were typically incubated 
overnight, DNAse (Fermentas) treated following the manufacturers protocol, and phenol 
chloroform extracted. Samples were diluted with formamide loading buffer and applied to 20% 
dPAGE gels, excised by UV shadowing and eluted in deionized water.  
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Figure B.1: 
 
Figure B.1. MALDI-MS spectra of platinated 5’-(U)6-GU-(U)5-3’ RNA. a) Smoothed, 
background subtracted MALDI-MS spectrum of platinated 5’-(U)6-GU-(U)5-3’ RNA.  Peaks 
assigned as indicated. b) Smoothed MALDI-MS spectrum of platinated 5’-(U)6-GU-(U)5-3’ 
RNA.  Rounded mass differences between different peaks indicated in blue. c) Unprocessed 
MALDI-MS spectrum of platinated 5’-(U)6-GU-(U)5-3’.  The calculated average mass of the un-
platinated RNA is 3957 amu. Addition of a [Pt(NH3)2-2H] fragment adds 227 amu (RNA + 
Pt(NH3)2 = 4184 amu). Peaks corresponding to additional Cl (35 amu) or aqua (18 amu) ligands 
are not observed.  
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Figure B.2: 
 
Figure B.2. VPD (3’à5’) digestion of platinated 5’-(U)6-GA-(U)5-3’ RNA.  MALDI-MS 
spectrum of the products of VPD digestion of platinated 5’-(U)6-GA-(U)5-3’ RNA.  The major 
peak represents digestion up to the internal A (calculated m/z = 2677, measured m/z = 2677).  
Digestion of an RNA containing a monofunctional [Pt(NH3)2X] adduct at G would be expected to 
give products corresponding to [Pt(NH3)2 + 5’-(U)6-G + H]+ (calculated m/z = 2347). The 
absence of such products is taken to indicate cisplatin diadducts forming at the GA pair. 
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Figure B.3: 
 
Figure B.3. MALDI-MS spectra of reactions involving 5’-(U)6-GA-(U)5-3’ RNA. MALDI-MS 
spectra of: a) the unmodified RNA; b) the platinated RNA; c) RNase U2 digestion products of the 
unmodified RNA; d) VPD digestion products of the platinated RNA; e) RNase U2 digestion 
products of the platinated RNA; f) SPD digestion products of the platinated RNA.   
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Figure B.4: 
 
Figure B.4. MALDI-MS spectra of reactions involving 5’-(U)6-GU-(U)5-3’ RNA. MALDI-MS 
spectra of: a) the unmodified RNA; b) the platinated RNA; c) RNase U2 digestion products of the 
unmodified RNA; d) VPD digestion products of the platinated RNA; e) RNase U2 digestion 
products of the platinated RNA; f) SPD digestion products of the platinated RNA.  
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Figure B.5: 
 
Figure B.5 MALDI-MS spectra of reactions involving 5’-(U)6-GG-(U)5-3’ RNA. MALDI-MS 
spectra of: a) the unmodified RNA; b) the platinated RNA; c) RNase U2 digestion products of the 
unmodified RNA; d) VPD digestion products of the platinated RNA; e) RNase U2 digestion 
products of the platinated RNA; f) SPD digestion products of the platinated RNA. (U)6-G and 
(U)5 peaks in (e) result from cleavage of un-platinated RNAs (RNA products were not separated 
following platination reactions).  The high relative intensity of these products reflects the low 
number of ions detected, overall, in this experiment and an observed bias for lower molecular 
weights during data collection over broad m/z ranges. 
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Figure B.6: 
 
Figure B.6. MALDI-MS spectra of reactions involving 5’-(U)6-AG-(U)5-3’ RNA. MALDI-MS 
spectra of: a) the unmodified RNA; b) the platinated RNA; c) RNase U2 digestion products of the 
unmodified RNA; d) VPD digestion products of the platinated RNA; e) RNase U2 digestion 
products of the platinated RNA; f) SPD digestion products of the platinated RNA. The 5’-(U)5 
products in (c) may be obscured by the formation of multiple alkali earth metal adducts, which 
can result in a spread of low-intensity peaks. 
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APPENDIX C 
 
SUPPORTING INFORMATION FOR CHAPTER IV: SITE-SPECIFIC PLATINUM(II) 
CROSSLINKING IN A RIBOZYME ACTIVE SITE 
 
 
Materials and Methods 
Nucleic Acid Substrates: RNA oligonucleotides were ordered from Dharmacon Inc., deprotected 
following the manufacturer’s protocol, dried by SpeedVac and resuspended in deionized water. 
Oligonucleotide concentrations were determined using a Varian Cary 300 Bio UV-visible 
spectrophotometer, measuring absorbance at 260 nm. MALDI-MS was routinely used to verify 
RNA quality before subsequent reaction. 
Cis-[Pt(NH3)2Cl(OH2)]+: Cis-Pt(NH3)2Cl2, (Sigma-Aldrich) was prepared as a 1 mM aqueous 
solution in 10 mM NaCl and stored in the dark at 4 °C. Immediately before use cis-Pt(NH3)2Cl2 
was aquated by reaction with 0.95 volume equiv. of 12 mM AgNO3 (stored in the dark). The 
aquation reaction was incubated at 50 °C for 1 h, at which time precipitated AgCl was removed 
by centrifugation. The resulting supernatant solution, 512 µM cis-[Pt(NH3)2Cl(OH2)]+, was 
removed and diluted accordingly. The predominant platinum species formed varies by pH with 
cis-[Pt(NH3)2Cl(OH2)]+ expected to be the main Pt-complex present at pH 7.0 (by 195Pt NMR, 
data not shown). 
Platination of HHrz constructs: A solution containing 400 pmol  (giving a final concentration 
of 40 µM) of each RNA strand used in an experiment was annealed by incubation at  90 °C for 90 
sec followed by slow cooling, and reacted with 120 µM cis-[Pt(NH3)2Cl(OH2)]+ (3:1 Pt:RNA 
ratio) in 1 mM Mg(NO3)2, 100 mM NaNO3, 10 mM Na2PO4, pH 7.0. Reactions were incubated 
for 16 h at 37 °C. Following this, reactions were diluted with formamide and analyzed using 20% 
dPAGE (19:1 mono- to bis- acrylamide, 7M urea), and visualized by staining with methylene 
blue. 
5’ End-Labeling: RNAs were radiolabeled with T4 polynucleotide kinase (New England 
Biolabs) using γ32P-ATP (Perkin-Elmer). End-labeled RNAs that were not further reacted with 
Pt(II) were purified using 20% dPAGE, excised from the gel and recovered as described below 
for Pt(II)-crosslinked products (vida infra). 
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Pt(II)-Crosslinking of 5’ End-Labeled RNA for Use in Mapping Studies: In order to increase 
the yield of radioactive crosslinked products, 5’ end-labeled RNAs were reacted with cis-
[Pt(NH3)2)(OH2)Cl]+ prior to gel purification. To do so, end-labeling reactions were diluted and 
protein was removed by phenol-chloroform extraction followed by two washes with 24:1 
chloroform:isoamyl alcohol. The RNA-containing aqueous phase was then desalted using G-25 
Sephadex size exclusion resin (GE Healthcare) on laboratory-prepared microcentifuge columns 
(BioRad) and dried to completion by SpeedVac. This 5’ end-labeled RNA was resuspended and 
used in platination reactions described above, with non-labeled RNA added as needed. 
Crosslinking reactions were diluted with formamide and analyzed by 20% dPAGE. Results were 
imaged using Molecular Dynamics phosphor screens scanned using a Storm 860 Scanner, and 
visualized using ImageQuant version 5.1 software (Molecular Dynamics). RNA bands were 
excised and eluted in 2 ml of 100 mM acetic acid, adjusted to pH 3.8 with TEMED. The acidity 
of this solution helps to prevent RNA degradation as well as potentially prevents hydrolysis 
reactions occurring at the Pt-phosphorothioate crosslink. After overnight elution, the RNA- 
containing eluent was removed and condensed using successive phase separations with n-
butanol.1 In this extraction procedure, a portion of the gel-eluted urea partitions into the organic 
phase and it is possible to obtain a very small RNA pellet, indicative of significantly desalted 
products. We believe that removing urea prior to the mild heating and condensation involved in 
SpeedVac drying may help preserve platinum crosslinks by preventing ligand substitution 
reactions at the crosslinked site. Dried and desalted RNAs were resuspended in deionized water.  
Hydrolysis Mapping of Pt(II)-Crosslinked RNAs: End-labeled, crosslinked RNAs in deionized 
water (typically 2 µL) were reacted with an equal volume of 50 mM Na2CO3/NaHCO3 (pH 9.5), 1 
mM EDTA and incubated at 90 °C for times ranging from 5 to 25 min. Reactions were quenched 
by the addition of 8 M urea, 10 mM sodium citrate (pH 3.5), 0.005% (w/v) xylene cyanol loading 
buffer and were held on dry ice until electrophoresis. Results were analyzed on 20% dPAGE gels 
and visualized via phosphorimaging. Reference lanes of 5′ end-labeled un-crosslinked RNAs 
were generated by alkali hydrolysis as described above as well as by partial nuclease digestion 
using RNase T1 (Ambion). Briefly, 5′ end-labeled RNA along with 0.2 µM unlabeled RNA was 
digested with 1U T1 RNase in 8 M urea, 10 mM sodium citrate (pH 3.5), and 0.005% (w/v) 
xylene cyanol at 50 °C for 12-15 min. These samples were similarly held on dry ice until 
electrophoresis. 
Pt(II)-Crosslinking Kinetics: Trace 5’ end-labeled SS(dC17, C1.1ps) was added to standard 
platination reactions using the HHrzES-SS(dC17, C1.1ps) construct. Aliquots were removed at 1, 
3, 5, 10, 15, 30, 45, 60, 240, and 480 min, quenched by mixture with formamide loading buffer 
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and held on dry ice until electrophoresis. Products were separated using 20% dPAGE and 
quantified using ImageQuant software. The kinetic traces obtained were fit using SigmaPlot 
version 11.0 (Systat Software, Inc.). A double exponential, 4 parameter equation of the form y = 
a(1-e-bx) + c(1-e-dx) provided the best fit to the data (R2 = 0.999). In this equation two reactive 
populations of the HHrzES-SS(dC17, C1.1ps) are portrayed: 18% of the total HHrz reacts with 
the reported kobs = 0.22 min-1 (0.0038 s-1), 15% reacts with kobs = 0.01 min-1 (1.6 x 10-4 s-1). These 
rates are divided by the concentration of Pt(II) used in the reactions to give calculated second 
order rate constants of 31 M-1 s-1 and 1.3 M-1 s-1 respectively. 
Molecular Modeling: The crystal structure of the Mn2+-containing HHrz (pdb:2OEU) was 
imported into Spartan ’08 (Wavefunction, Inc.) Version 1.2.0.  Sulfur substitutions were made at 
individual non-bridging oxygens of the phosphodiester bonds between C17-C1.1 as well as 
between C1.1-U1.2 to produce R and S stereoisomers of each phosphorothioate. Bond lengths and 
angles of the Pt-S-P unit were fixed based on previously reported NMR studies2 and a crystal 
structure of a phosphorothioate-bound Pt-terpyridine complex.3 For each stereoisomer, a square-
planar [Pt(NH3)2(OH2)] fragment was attached to the phosphorothioate sulfur ligand. All heavy 
atoms in the structure, except for the G10.1/A9-coordinated Mn2+ which was removed, were then 
held static except for the phosphorothioate S and attached [Pt(NH3)2(OH2)]  fragment. It is 
recognized that this procedure neglects the inherent flexibility of the RNA biopolymer, and 
suggests further studies in order to understand how structural dynamics may contribute to the 
formation of Pt crosslinks. Several constraints were then placed on Pt coordination geometry and 
bond lengths: 90˚ bond angles were enforced between platinum substituents, the Pt-S-P bond 
angle was fixed at 98˚ based on the Pt-terpyridine structure,[3] and fixed bond lengths were 
derived from related reports.3,4   Structures were then minimized using built-in molecular 
mechanics (MMFF) algorithms. The obtained structures were exported as “.pdb” files into Pymol 
Molecular Graphics System version 1.2r3pre which was used to measure distances and generate 
figure graphics. 
Cleavage at Phosphorothioate Substitutions by cis-[Pt(NH3)2Cl(OH2)]+: In order to test the 
ability of cis-[Pt(NH3)2Cl(OH2)]+ to cleave at phosphorothioate substitutions, the RNA sequence 
5’-UUUUCpsCUUUU-3’ was obtained (Dharmacon Inc.). A 40 µM solution (final 
concentration) of this RNA was reacted with 120 µM cis-[Pt(NH3)2Cl(OH2)]+  in 1 mM 
Mg(NO3)2, 100 mM NaNO3, 10 mM Na2PO4, pH 7.0. Reactions were incubated for 16 h at 37 °C 
and desalted prior to MALDI-MS using C18 ZipTips (Millipore). In this procedure ZipTips were 
washed by aspiration three times with 1:1 MeCN:H2O, and equilibrated by washing three times 
with 0.1% trifluoroacetic acid (TFA). RNAs were bound to the tip by repeated aspiration of the 
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analyte solution. Bound RNA was washed three times by aspiration with 0.1% TFA, three times 
with deionized water, and then eluted from the column using two washes of 1:1 MeCN:H2O. This 
eluent was dried to completion by SpeedVac. 
MALDI-MS: Dried RNA samples were resuspended in a matrix consisting of 375 mM 2’,4’,6’-
trihydroxyacetophenone (THAP, Sigma-Aldrich), 30 mM diammonium citrate in 3:1 EtOH:H2O, 
with added NH4+ loaded Dowex cation exchange beads (Aldrich) and applied to the sample plate. 
MALDI-MS analysis was performed on a Waters QToF Premier mass spectrometer in positive-
ion mode using V-mode optics. 
Reversal of Pt-Phosphorothioate Crosslinks by Thiourea. Trace amounts of 5’ end-labeled, 
crosslinked RNAs in deionized water were reacted with an equal volume of a saturated thiourea 
solution and incubated at 37 oC  for times ranging from 1 to 28 h. Short reactions, including the 
“0” time point, were held on dry ice while others completed. Results were analyzed using 20% 
dPAGE and visualized by phosphorimaging. 
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Figure C.1: 
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Figure C.1. Location of Pt(II) crosslinks formed in the HHrzES-SS(dC17, C1.1ps) ribozyme. a) 
Secondary structure of the HHrzES-SS(dC17, C1.1ps) construct. b) 20% dPAGE gel displaying 
the loss of hydrolysis products 3’ to nucleotide U16, indicating crosslinking 3‘ to this location. 
Hydrolysis products are not expected at dC17 regardless of crosslinking. The absence of 
hydrolysis products 3‘ to dC17 however, indicates crosslinking to the C1.1 phosphorothioate. 
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Figure C.2: 
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Figure C.2. Spartan ’08 generated molecular models of a [Pt(NH3)2(OH2)] fragment bound to 
phosphorothioate substitutions in the HHrz. [Pt(NH3)2(OH2)] bound to a) the R stereoisomer of 
the C1.1 phosphorothioate; b) the S stereoisomer of the C1.1 phosphorothioate; c) the R 
stereoisomer of the U1.2 phosphorothioate; d) the S stereoisomer of the U1.2 phosphorothioate. 
Distances between Pt(II) atom and nearby purine N7 positions are indicated. The “*” 
representation at G1.4 indicates a G nucleotide at this position in the 2OEU structure used for this 
model that was not present in the HHrz construct used in the work. 
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Figure C.3: 
 
Figure C.3.  MALDI-MS spectra depicting Pt(II)-induced cleavage of 5’-UUUUCpsCUUUU-3’. 
a) Control 5’-UUUUCpsCUUUU-3’ RNA. b) Spectrum obtained following incubation of 5’-
UUUUCpsCUUUU-3’ with cis-[Pt(NH3)2Cl(OH2)]+ as described in Materials and Methods. c) 
Expanded view of the spectrum shown in (b) showing products from cleavage at the C*C 
phosphorothioate following treatment with cis-[Pt(NH3)2)(OH2)Cl]+. Notably, the 5’-cleavage 
fragment has a 2’,3’ cyclic phosphate indicating intramolecular nucleophilic attack at the 
platinated site. The platinum is not observed to be bound to either RNA fragment. Secondary 
peaks result from commonly observed (and difficult to fully eliminate) alkali earth metal adducts 
of each species.  
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Figure C.4: 
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Figure C.4. 20% dPAGE gel depicting the lack of intermolecular crosslinking between HHrzES 
and SS(dC7, U1.2ps) RNAs following platination.  Unlike the case for C1.1ps, the platinated 
U1.2ps does not form intermolecular crosslinks with the HHRz enzyme strand. Lanes shown are 
as in Figure 1 of the paper: SS(dC17, U1.2ps) alone, ES alone, ES:SS(dC17, U1.2ps), and ES:SS 
(no phosphorothioate), incubated in presence and absence of [Pt(NH3)2Cl(OH2)]+. 
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Figure C.5: 
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Figure C.5. Attempted crosslinking of phosphorothioate-substituted RNAs to a base-paired 
complement. a) Sequences of the SS and SSComp RNAs; b) 20% dPAGE  gel depicting the lack 
of intermolecular crosslinking between SS(dC17, C1.1ps) and SS(Comp) RNAs following 
platination; c) 20% dPAGE  gel depicting the lack of intermolecular crosslinking between 
SS(dC17, U1.2ps) and SSComp RNAs following platination. Platination conditions are identical 
to those used for HHrz ES:SS experiments. 
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Figure C.6: 
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Figure C.6. Reversal of Pt(II)-phosphorothioate crosslinks using thiourea. 20% dPAGE gel 
depicting the reversal of Pt(II)-phosphorothioate crosslinks in the HHrz ES:SS(dC17, C1.1ps) 
complex by thiourea. Release of the 5’-end labeled HHrz enzyme strand is observed.  
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APPENDIX D 
 
SUPPORTING INFORMATION FOR CHAPTER V: PLATINUM(II) ACTIVATED 
CLEAVAGE, DESULFURIZATION AND ISOMERIZATION OF 
PHOSPHOROTHIOATE SUBSTITUTED RNAS 
 
 
Materials and Methods:  
Nucleic Acid Substrates: All RNA oligonucleotides used in this work were purchased from 
Dharmacon Inc. and deprotected following the manufacturer’s protocol. Oligonucleotide 
concentrations were determined using a Varian Cary 300 Bio UV-visible spectrophotometer, 
monitoring absorption at 260 nm. 
Cis-Pt(NH3)2Cl2 Aquation: Cis-Pt(NH3)2Cl2, (Sigma-Aldrich) was prepared as a 1 mM aqueous 
solution in 10 mM NaCl and stored in the dark at 4 °C. Immediately before use cis-Pt(NH3)2Cl2 
was aquated by reaction with 0.95 volume equiv. of 12 mM AgNO3 (stored in the dark). The 
aquation reaction was incubated at 50 °C for 1 h, at which time precipitated AgCl was removed 
by centrifugation. The resulting supernatant solution, a 512 µM mixture of cis-Pt(II) species, was 
removed and diluted accordingly. The predominant platinum species formed varies by pH with 
cis-[Pt(NH3)2Cl(OH2)]+ expected to be the main Pt-complex present at pH 7.0 (by 195Pt NMR, 
data not shown). 
Standard Platination Conditions: Typically, 40 µM RNA was reacted with 120 µM aquated 
cis-Pt(II) species in a background of 1 mM Mg(NO3)2, 100 mM Na(NO3), 10 mM MES (2-(N-
morpholino)ethanesulfonic acid) pH 6.5 at 37° C for the times indicated in the text. Reactions 
were typically carried out on a 10 µL scale. Reactions were then stopped by freezing on dry ice at 
-78° C and held there until purified by C18 ZipTips and analyzed by MALDI-MS.  
MALDI-MS: RNA samples were purified using C18 ZipTips using a procedure modified from 
the manufacturer’s protocol for RNA. ZipTips were washed by aspiration three times with 1:1 
MeCN/H2O solution, and equilibrated by washing three times with 0.1% trifluoroacetic acid 
(TFA). RNAs were bound to the tip by repeated aspiration of the analyte solution. Bound RNA 
was washed three times by aspiration with 0.1% TFA, three times with deionized water, and then 
eluted from the column using two washes of 1:1 MeCN/H2O. The eluent was dried to completion 
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by SpeedVac and resuspended in a matrix consisting of 375 mM 2′,4′,6′ trihydroxyacetophenone 
(THAP, Sigma-Aldrich), 30 mM diammonium citrate in 3:1 EtOH/H2O, with added NH4+ loaded 
Dowex cation exchange beads (Aldrich) and applied to the sample plate. MALDI-MS analysis 
was performed on a Waters QToF Premier mass spectrometer in positive-ion mode using V-mode 
optics. 
pH Dependent MALDI-MS: Reactions were carried out using the standard platination 
conditions as described above with the identity and pH of the buffer varied as follows: pH 3.5- 
10mM sodium acetate, pH 5.5- 10mM MES, pH 6.5 10mM MES, pH 8.0- 10 mM TRIS 
(tris(hydroxymethyl)aminomethane). The pH of buffered solutions was adjusted using HNO3 and 
NaOH. 
5’ End-Labeling:  The 10-mer PS-containing RNA, 5’-UUUUCpsUUUU-3’ was radiolabeled 
with T4 poly nucleotide kinase (Fermentas) using γ32P-ATP (Perkin-Elmer). End-labeled RNA 
was purified by 20% dPAGE, imaged by phosphor screen and excised. Excised gel bands were 
eluted overnight in deionized water. The resulting eluent was concentrated and desalted using G-
25 Sephadex spin-columns. 
pH Dependent Cleavage Kinetics: Trace 5’ end-labeled RNA was added to the standard 
platination reactions described above, with pH varied as described. Typically, the volume of these 
reactions was scaled three fold (from 10 µL to 30 µL). Typically, 2 µL aliquots from each 
reaction were removed at appropriate time points and held on dry ice until electrophoresis. 
Immediately prior to electrophoresis, samples were mixed with formamide loading buffer 
(containing 0.005% (w/v) xylene cyanol and bromophenol blue). Reactions were analyzed using 
20% dPAGE (7M urea), imaged by phosphorimaging. ImageQuant version 5.0 software 
(Molecular Dynamics) was used to quantify band intensities. SigmaPlot version 11.0 (Systat 
Software, Inc.) was used to generate kinetic traces.  
NMR Spectroscopy. 1mM 5’-UpsU-3’ RNA was combined with 1.5 mM aquated cis-Pt(II) 
species in 100 mM NaNO3, 1 mM Mg(NO3)2, 10 mM HEPES, at pH 7.5 and 25°C (10% D2O in 
water). When not being analyzed by NMR, the reaction was stored, protected from light, at room 
temperature. All RNA samples were placed in Shegemi D2O matched quartz tubes (Shegemi Inc., 
Allison Park, PA). 1H-decoupled 31P NMR spectra were recorded at 202 Mhz on a Varian Unity 
spectrometer.  
DFT Calculations: DFT calculations were performed using Spartan ’08 (Wavefunction, Inc.) 
Version 1.2.0. Equilibrium geometries were optimized using the B3LYP functional with the 
LAVCP extended 6-31*G basis set. Atomic electrostatic potentials were calculated using the 
same level of theory. Electrostatic potential maps were generated using built-in software features. 
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Figure D.1: 
 
[Pt n(NH3)2nSn]Na 
n=1 
n=2 
n=3 
n=4 
! Na 
! Na ! Na 
 
Figure D.1. MALDI-MS spectra depicting low nuclearity Pt complexes observed to result from 
the reaction of cis-Pt(II) species with PS-substituted RNAs. 
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Table D.1: 
Metal Complex Aqueous 
Metal Ion  
Cleavage  Desulfurization 
cis-Pt(NH3)2Cl2 Pt(II) + + 
trans-Pt(NH3)2Cl2 Pt(II) + + 
PtCl4 Pt(II) + + 
AgNO3 Ag(I) - + 
Zn(CH3CO2)2 Zn(II) - - 
CoSO4 Co(II) - - 
NiSO4 Ni(II) - - 
Mn(CH3CO2)2 Mn(II) - - 
Co(NO3) Co(II) - - 
CaCl Ca(II) - - 
LiCl Li(I) - - 
CuSO4 Cu(II) - - 
TbCl3 Tb(III) - - 
Fe(NH4)2(SO4)2 Fe(II) - - 
Cu(CH3CN)4 Cu(I) - - 
CsCl Cs(I) - - 
Cd(NO3)2 Cd(II) - - 
 
Table D.1. Summary of the results obtained following the reaction of various metal ions with 5’-
UUUUCpsCUUUU-3’. Conditions: 40 µM RNA reacted with 120 µM metal in a background of 1 
mM Mg(NO3)2, 100 mM Na(NO3), 10 mM MES, pH 6.5, 37° C for 16 hr.  
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